

Review

# Biological Activity of Naturally Derived Naphthyridines

Gabriela Chabowska <sup>1</sup>, Ewa Barg <sup>1,\*</sup> and Anna Wójcicka <sup>2,\*</sup>

<sup>1</sup> Department of Basic Medical Sciences, Faculty of Pharmacy, Wrocław Medical University, Borowska 211A, 50-556 Wrocław, Poland; gabriela.chabowska@student.umed.wroc.pl

<sup>2</sup> Department of Pharmaceutical Technology, Faculty of Pharmacy, Wrocław Medical University, Borowska 211A, 50-556 Wrocław, Poland

\* Correspondence: ewa.barg@umed.wroc.pl (E.B.); anna.wojcicka@umed.wroc.pl (A.W.);  
Tel.: +48-71-784-0477 (E.B.); +48-71-784-0246 (A.W.)

**Abstract:** Marine and terrestrial environments are rich sources of various bioactive substances, which have been used by humans since prehistoric times. Nowadays, due to advances in chemical sciences, new substances are still discovered, and their chemical structures and biological properties are constantly explored. Drugs obtained from natural sources are used commonly in medicine, particularly in cancer and infectious diseases treatment. Naphthyridines, isolated mainly from marine organisms and terrestrial plants, represent prominent examples of naturally derived agents. They are a class of heterocyclic compounds containing a fused system of two pyridine rings, possessing six isomers depending on the nitrogen atom's location. In this review, biological activity of naphthyridines obtained from various natural sources was summarized. According to previous studies, the naphthyridine alkaloids displayed multiple activities, i.e., antiinfectious, anticancer, neurological, psychotropic, affecting cardiovascular system, and immune response. Their wide range of activity makes them a fascinating object of research with prospects for use in therapeutic purposes.

**Keywords:** natural compounds; alkaloids; naphthyridines; heterocyclic compounds; canthin-6-one; aaptamine; pyridoacridines; biological activity



**Citation:** Chabowska, G.; Barg, E.; Wójcicka, A. Biological Activity of Naturally Derived Naphthyridines. *Molecules* **2021**, *26*, 4324. <https://doi.org/10.3390/molecules26144324>

Academic Editor: Owen M. McDougal

Received: 29 May 2021

Accepted: 13 July 2021

Published: 16 July 2021

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

The natural environment abounds in substances with multiple biological properties that have become an inspiration and basis for modern drugs. Since prehistoric times, secondary metabolites especially in the form of plant materials have been used for therapeutic purposes [1]. Nowadays, thanks to chemical sciences development, natural derivatives can be isolated from terrestrial and marine sources as multi-component extracts or single compounds. This provides a possibility to explore their properties, from chemical structures and general mechanisms of action to more specialized molecular targets.

Naphthyridines are a class of heterocyclic compounds that are also referred to in the chemical literature as “benzodiazines” or “diazanaphthalenes”, due to possessing a fused system of two pyridine rings. There are six positional isomers with different locations of nitrogen atoms (Figure 1).

The compounds containing the naphthyridine scaffold are found in natural products (plants and marine organisms) or can be obtained synthetically. The properties and synthesis of 1,8-isomer derivatives were most often described, mainly due to nalidixic acid (1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid), which was discovered by G. Leshner in 1962 [2] and introduced into treatment in 1967 as an antibacterial drug. In the last several decades, scientists' interest in naphthyridines has been growing due to their broad spectrum of biological activity. In this review, biological activity of naphthyridines derived exclusively from the natural environment is presented. Many of them revealed significant bioactivity and this article may encourage researchers to further the investigation of these chemical compounds.




Figure 1. Isomeric forms of naphthyridines.

## 2. Naturally Occurring Naphthyridine Derivatives

### 2.1. 1,5-Naphthyridine Derivatives

1,5-Naphthyridine natural products are represented primarily by canthinone-type alkaloids. A major member of the group, canthin-6-one **1** (Figure 2), is isolated primarily from plants—the *Rutaceae* and *Simaroubaceae* families, but also from fungi [3]. The immunomodulatory activity of the compound has been determined. In rats with drug-induced colitis, canthin-6-one **1** reduced the production of pro-inflammatory mediators TNF- $\alpha$  (tumor necrosis factor  $\alpha$ ), IL-1 $\beta$  (interleukin-1 $\beta$ ), IL-12p70 (interleukin-12p70), and VEGF (vascular endothelial growth factor). Moreover, it diminished oxidative stress in colon tissues [4].




Figure 2. Structure of canthin-6-one derivatives.

Moreover, canthin-6-one **1** has been studied for its anticancer properties. Normally, cell death determines system homeostasis and prevents excessive proliferation and accumulation of defective cells. Major mechanisms of cell death comprise programmed apoptosis and autophagy, and traumatic necrosis. In cancer cells, cell death is disturbed due to genetic abnormalities. Restoration of a proper cell cycle together with generating cell damage in tumor tissues are key targets for anticancer compounds.

Canthin-6-one **1** was shown to activate apoptosis and necrosis in Kasumi-1 human myeloid leukemia cells, with cell cycle arrest at G<sub>0</sub>/G<sub>1</sub> and G<sub>2</sub>, respectively, at 7  $\mu$ M and 45  $\mu$ M. The agent also induced cancer cells differentiation, a process which could potentially lead to the conversion of neoplastic cells into normal [5].

1,5-Naphthyridine representatives were also obtained from *Zanthoxylum paracanthum* *Kokwaro*—an endemic, tropical plant, native to Kenya and Tanzania. Canthin-6-one and


10-methoxycanthin-6-one **2** (Figure 2), isolated from the species, have been regarded as promising antibacterial and antifungal substances [6]. They displayed strong inhibitory activity against *Staphylococcus aureus* and *Escherichia coli* (MIC values respectively of 0.49 and 3.91 µg/mL), and importantly also against methicillin-resistant *Staphylococcus aureus* strain (MIC values respectively 0.98, 3.91 µg/mL). The results of stronger canthin-6-one **1** were similar to that of reference omacilin. Antifungal effects of the compounds **1–2** were presented with MIC values, respectively, of 3.91 and 7.81 µg/mL for canthin-6-one **1** and 10-methoxycanthin-6-one **2**. The compounds **1–2** also exerted significant anticancer effects against DU145 prostate and HCC 1395 human breast cancer cell lines, with the most impressive activity of 10-methoxycanthin-6-one **2** against DU145 (IC<sub>50</sub> = 1.58 µg/mL, and SI = 34.15) [6].

*Ailanthus altissima Swingle* has been considered as another natural source of 1,5-naphthyridines. It is a genus of tree distributed primarily in China, but is now widespread in Europe and North America. Healing properties of the plant are known in traditional medicine, and it is used i.a. in treating bacterial infections, fever and diarrheas. Kim et al. isolated six canthinone-type compounds, containing the 1,5-naphthyridine ring, from the bark of *Ailanthus altissima Swingle* [7]. The derivatives were determined as (*R*)-5-(1-hydroxyethyl)-canthine-6-one **3**, canthin-6-one **1**, 4-hydroxycanthin-6-one **4**, 10-hydroxycanthin-6-one **5**, 9-hydroxycanthin-6-one **6**, and 11-hydroxycanthin-6-one **7** (Figure 2). The compounds **1** and **3–7** were tested for their anti-inflammatory properties. Derivatives **1–5** showed strong inhibitory effect on LPS (lipopolysaccharides)-induced NO (nitric oxide) production in RAW 264.7 murine macrophage cell line (IC<sub>50</sub> = 7.73–15.09 µM). Moreover, 10-hydroxycanthin-6-one showed antifungal activity against *Fusarium graminearum* and *Fusarium solani* (growth inhibition rates respectively of 74.5% and 57.9%), and antibacterial effect against *Bacillus cereus* (MIC = 15.62 µg/mL) [8]. Canthin-6-one displayed antiparasitic effect in mice infected with *Trypanosoma cruzi*, both in acute and chronic infection. Due to its low toxicity, it is considered a promising candidate in Chagas disease therapy [9]. Canthin-6-one and 8-hydroxy-canthin-6-one **8** were also shown to exert antimycobacterial effects [10].

1,5-Naphthyridine alkaloids were isolated also from *Leitneria floridana*, a species of shrub, commonly known as corkwood, which is distributed in the southern regions of the United States. *Leitneria floridana*-derived 1-methoxycanthin-6-one **9** appeared to exert an effect against HIV (Human Immunodeficiency Virus) with an EC<sub>50</sub> value of 0.26 g/mL [11]. Beside antiviral properties, the compound displayed anticancer potency and was shown to induce cellular apoptosis by activation of c-Jun N-terminal kinase [12].


The protein complex NF-κB (nuclear factor kappa B) plays a key role in pro-inflammatory mechanisms and has been found chronically active in various types of tumors and autoimmune diseases. A study performed by Tran et al. showed that *Eurycoma longifolia*-derived alkaloids: 9-hydroxycanthin-6-one **6**, 9-methoxycanthin-6-one **10** and 9,10-dimethoxycanthin-6-one **11** (Figure 2) significantly inhibited NF-κB transcription with IC<sub>50</sub> values in the range of 3.8–19.5 µM [13]. In another study, *Brucea mollis*-isolated 9-methoxycanthin-6-one **10** exerted strong cytotoxic properties against KB epidermoid carcinoma, LU-1 lung adenocarcinoma, LNCaP prostate adenocarcinoma, and HL-60 leukemia human cell lines with IC<sub>50</sub> values in the range of 0.91–3.73 µM [14].

*Picrasma quassioides*, a genus of tree commonly growing in temperate regions of southern Asia, revealed to be the source of another natural naphthyridine agents. Jiao et al. isolated novel 1,5-naphthyridine alkaloids from *Picrasma quassioides Bennet* [15]. The compounds were determined as quassidine E **12** and canthin-16-one-14-butyric acid **13** (Figure 3). The novel agents **12** and **13** reduced the production of pro-inflammatory mediators: NO, IL-6, and TNF-α in LPS-induced RAW 264.7 cells, with IC<sub>50</sub> values in the range of 20.51–66.96 µM [15].



**Figure 3.** Structures of quassidine E **12** and canthin-16-one-14-butyric acid **13**.

Natural products—cimiciduphytine **14** and eburnane derivatives **15** (Figure 4)—were evaluated as natural painkillers and antihypertensive agents, which could be used in cerebral circulation disturbance therapy [16].



**Figure 4.** Structures of cimiciduphytine **14** and eburnane derivatives **15**.

## 2.2. 1,6-Naphthyridine Derivatives

*Aptos*, a widely-known genus of marine sponges, is considered as a prominent natural source of 1,6-naphthyridines. *Aptos* was firstly described by Gray in 1867 [17]. The genus is represented by nearly 29 species that can be found in shallow waters of coastal areas all over the world. Since the 1980s, *Aptos* has been extensively researched due to being the source of at least 62 secondary metabolites with diverse biological activities [18].

Aptamine (8,9-dimethoxy-1*H*-benzo[*de*][1,6]naphthyridine) **16** (Figure 5) isolated by Nakamura et al. [19] in 1982 from *Aptos aptos* became the first, maternity representative of aptamines family. The anticancer activity of the compound **16** has been extensively researched. Aptamine exhibited notable cytotoxic effects in vitro against H1299 and A549 non-small cell lung cancer [20], HeLa cervical cancer [21], and CEM-SS T-lymphoblastic leukemia cell lines [22], with IC<sub>50</sub> values ranging from 10.47 to 15.03 µg/mL. Moreover, aptamine **16** displayed a potent anticancer effect in mice carrying human hepatocellular carcinoma HCC-LM3 xenografts with downregulation of SOX9 and Ki67 expression [23]. The agent **16** has been detected to intercalate into DNA [24], upregulate p21 expression, and induce apoptosis in cancer cells in a p53-independent manner [23,25]. Aptamine **16**

expressed the ability to interfere specifically with p53 and c-myc network in NT2 human embryonal carcinoma cell line [26]. Gong et al. [20] performed further investigation of the mechanism of aaptamine **16** action in non-small cell lung cancer cell lines. The agent **16** displayed antiproliferative properties with inhibition of cancer cells growth and clonogenicity in a dose-dependent manner. Aaptamine induced G1 cell cycle arrest with a reduction of CDK2 (Cyclin-dependent kinase 2), CDK4 (Cyclin-dependent kinase 4), Cyclin D1, and Cyclin E levels, and also interfered with the PI3K/AKT/GSK3 $\beta$  (phosphatidylinositol-3 kinase/protein kinase B/glycogen synthase kinase 3 beta) axis. It could potentially diminish the process of metastasis and tumor invasion due to downregulation of MMP-7 (matrix metalloproteinase-7) and MMP-9 (matrix metalloproteinase-9) expression [20]. Beside anticancer activity, aaptamine **16** was shown to block  $\alpha$ -adrenoceptors in vascular smooth muscles [27]. Hence, it could be considered a antihypertensive agent. Moreover, the compound **16** has been reported to display antiviral activity against HIV-1 [24] and anti-amoebic effect towards *Acanthamoeba castellanii* [28]. Aaptamine **16** selectively blocked the type A MAO (Monoamine Oxidase) [29], an enzyme which is overexpressed in the brain during major depression episodes. Therefore, aaptamine **16** could be useful in depression therapy. Aaptamine **16** demonstrated a wide range of activity, nevertheless its derivatives surpassed the effect of parental agent.




Figure 5. Aaptamine derivatives **16**–**18**.

There are several studies comparing properties of parent aaptamine **16** with its derivatives demethyl(oxy)aaptamine **17** and iso-aaptamine **18** (Figure 5). Dyshlovoy et al. [30] investigated anticancer properties of these compounds **16**–**18**, isolated from *Aaptos*. Evaluation of cytotoxicity on human cancer cell lines (THP-1 human leukemia monocytic, HeLa cervical cancer, SNU-C4 colorectal carcinoma, SK-MEL-28 human melanoma, MDA-MB-231 breast cancer) in MTS assay confirmed significant anticancer potency of aaptamines **16**–**18**, and aaptamine analogues exerted impressively higher activity than the parent compound. All the agents **16**–**18** induced apoptosis in THP-1 cell line, and the effect was also more significant for demethyl(oxy)aaptamine **17** and iso-aaptamine **18**. The study confirmed p53-independent cell cycle arrest induced by these compounds **16**–**18**. The agents **16**–**18** were also shown to prevent cancerogenesis induced by epidermal growth factor at low, non-toxic concentrations in the JB6 P+ Cl41 murine epidermal cell line. The mechanism of prevention is independent from the transcription of AP-1 (activator protein-1) and NF- $\kappa$ B.

Wu et al. [31] investigated the cytotoxicity of aaptamine **16**, demethyl(oxy)aaptamine **17**, and iso-aaptamine **18** on breast cancer cell lines. The derivatives **17** and **18** also presented higher activity than parent compound **16**. Iso-aaptamine **18** exerted the highest effect on T-47D (IC<sub>50</sub> = 30.13  $\mu$ M), meanwhile demethyl(oxy)aaptamine **17** was the most potent on MCF-7 (IC<sub>50</sub> = 23.11  $\mu$ M) and MDA-MB-231 (IC<sub>50</sub> = 19.34  $\mu$ M) cell lines. Iso-aaptamine **18**, chosen for further research as the most prominent alkaloid (84.74%) in the active fraction isolated from sponge *Aaptos* sp., presented short-term and long-term antiproliferative properties. The compound **18** inhibited XIAP (X-linked inhibitor of apoptosis protein) expression, and due to caspases 3 and 7 activation and cleavage of PARP (Poly ADP-ribose polymerase), induced apoptotic cell death in cancer cells. Cytotoxic properties of

isoaaptamine **18** have also been based on autophagy induction, disruption to mitochondrial function, and over-generating reactive oxygen species. The role of isoaaptamine **18** as a significant apoptosis inducer on THP-1 cells was confirmed by Shubina et al. [32]. The compound **18** exerted the highest activity among tested aaptamine analogues.

Beside aaptamine **16** and its major analogues demethyl(oxy)aaptamine **17** and isoaaptamine **18**, other 1,6-naphthyridines have been successfully isolated from marine sponge *Aaptos*. Liu et al. [33] obtained four novel 1,6-naphthyridine alkaloids, suberitine A-D **19–22** (Figure 6), and two known alkaloids, demethyl(oxy)aaptamine **17** (Figure 5) and 8,9,9-trimethoxy-9H-benzo[de][1,6]naphthyridine **23** (Figure 7), from the *Aaptos suberitoides*.




Figure 6. Structures of suberitines A-D **19–22**.




Figure 7. Structure of 8,9,9-trimethoxy-9H-benzo[de][1,6]naphthyridine **23** and 1,3-dioxolo[4,5-d]benzo[de][1,6]naphthyridine **24**.

Cytotoxic evaluation of the compounds revealed significant antitumor activity of **20** and **22** against P388 cell line with  $IC_{50}$  values, respectively, of 1.8 and 3.5  $\mu\text{M}$  [33].

Toshiyuki Hamada et al. [34] isolated 8,9,9-trimethoxy-9H-benzo[de][1,6]naphthyridine **23** and 1,3-dioxolo[4,5-d]benzo[de][1,6]naphthyridine **24** (Figure 7) from the Bornean *Aaptos aaptos* and tested their cytotoxicity against adult T-cell leukemia cells. Compound **24** revealed a significant antitumor effect with an  $IC_{50}$  value of 0.29  $\mu\text{M}$ , while alkaloid **23** remained inactive.

Yu et al. [35] isolated nine novel and three previously-known aaptamine derivatives from the South China Sea sponge *Aaptos aaptos*. Four of the compounds: 9-Amino-2-ethoxy-8-methoxy-3H-benzo[de][1,6]naphthyridin-3-one **25**, 3-isobutylaminodemethyl(oxy)

aaptamine **26**, 3-(isopentylamino)demethyl(oxy)aaptamine **27**, and 3-(phenethylamino)demethyl(oxy)aaptamine **28** (Figure 8) revealed potent anticancer activity with  $IC_{50}$  values in the range of 0.03–8.5  $\mu$ M against human cancer cell lines: HL60 leukemia, K562 erythroleukemia, MCF-7 breast cancer, KB epidermoid carcinoma, HepG2 hepatocellular carcinoma, and HT-29 colon adenocarcinoma [35].




Figure 8. Structures of aptamine derivatives 25–28.

RANKL (Receptor Activator for Nuclear Factor  $\kappa$ B Ligand) is a transmembrane protein that controls bone regeneration and remodeling. Wang et al. [36] performed biological examination of four 1,6-naphthyridines analogues, aaptodine A–D **29** (Figure 9), derived from *Aptos suberitoides*. Aaptodine A–D **29** inhibited impressively RANKL-induced osteoclast formation and resorption, with the strongest effect for aaptodine D **29D**. Hence, aaptodines could be considered as candidates for drugs used in treating osteoporosis and hormone therapy-induced bone loss.




Figure 9. Structures of aaptodine A–D **29**.

Another rich source of 1,6-naphthyridine is constituted by *Sophora* derivatives. Trees and shrubs from genus *Sophora*, comprising approximately 62 species, are distributed in tropical and temperate zones in Eastern Europe; Asia; Australia; Pacific islands; and western, North, and South America. Natural alkaloids have been isolated from roots, seeds and epigeal parts of the plant. *Sophora* extracts have been used in traditional Chinese medicine [37].

Matrine **30** (Figure 10) is considered as one of the most principal and widely studied *Sophora* alkaloid, and the number of publications regarding the compound are constantly growing. Molecular mechanisms of matrine **30** antitumor activity have been considerably researched. Recent studies confirmed the antineoplasm effect of matrine on MCF-7 breast cancer and A549 non-small cell lung cancer cell lines by inhibiting AKT/mTOR axis [38,39]. Additionally, it reduced tumor growth of ovarian cancer cells in vivo by inducing the expression of ERK and JNK (c-Jun N-terminal kinase) pathways [40]. Matrine **30** also

exerted a significant effect in drug-resistant tumors by inducing apoptosis and inhibiting efflux-pump activity [41,42]. Beside anticancer properties, matrine **30** exerted cardioprotective effects towards cardiomyocyte damage during hyperglycemia and sepsis [43,44]. Moreover, matrine **30** properties of protecting liver function resulted in several clinical trials. Intramuscular injections of matrine **30** caused improvement of condition in patients treated for chronic Hepatitis type B and patients suffering from primary hepatic carcinoma after trans-artery chemo-embolization [45,46]. Compound **30** was also reported to decrease total bilirubin level and improve survival rates in liver transplant recipients [47]. Matrine **30** is also considered a promising candidate as an immunosuppressive drug due to inhibiting autoimmune response in experimental models of multiple sclerosis [48,49]. It also exerts antiviral activity [50,51].




Figure 10. Structures of the Sophora alkaloids 30–33.

Extract isolated from the seeds of *Sophora alopecuroides* matrine **30**, sophocarpine **31** and sophoramine **32** (Figure 10), with contents, respectively, of 32.85%, 26.55%, and 6.91%, have alleviated morphine withdrawal in patients [52]. Moreover, these alkaloids **30–33** displayed strong antitumor properties. Matrine **30**, sophoridine **33** (Figure 10), and sophocarpine **31** exerted potent cytotoxic activity against HL-60 human leukemia, U937 human myeloid leukemia, K562 human erythroleukemia, EC109 esophageal squamous cell carcinoma, A549 non-small cell lung cancer, and HepG2 hepatocellular carcinoma cell lines, with  $IC_{50}$  values in the range of 1.21–12.86 mM [53]. Matrine **30** and sophocarpine **31** decreased cachexia symptoms (induced by colon carcinoma) in mice, and the mechanism of action was related to the suppression of  $TNF-\alpha$  and IL-6 production [54]. Additionally, sophoramine **32** and sophocarpine **31** displayed antinematocidal activity against *Bursaphelenchus xylophilus*, pine trees parasite, and it was observed that degree of unsaturation in the -lactam ring correlated with the strength of antinematocidal activity [55].

*Sophora* alkaloids have been tested worldwide for their anti-inflammatory properties. Tang et al. [56] evaluated the activity of five 1,6-naphthyridines analogues **34–36** (Figure 11), derived from roots of *Sophora tonkinensis*. The agents **34–36** significantly reduced the secretion of cytokines  $TNF-\alpha$  and IL-6 in LPS-stimulated murine macrophages RAW 264.7. The most potent effect, higher than that of matrine **30**, was exerted by 12,13-dehydrosophoridine **34** ( $TNF-\alpha$  and IL-6 levels were 56.82% and 65.21%, respectively) [56].






Figure 11. Sophoridine derivatives 34–36.

Li et al. [57] isolated 43 natural alkaloids from the seeds of *Sophora alopecuroides*. Assessment of anti-inflammatory efficacy was measured as suppression of NO production in LPS-activated RAW 264.7 cells. Among *Sophora* alkaloids, 5,6-dehydrolupanine **37** (Figure 12) exerted the most potent effect ( $IC_{50}$  value of 25.86  $\mu$ M), higher than that of matrine. On the other hand, another 1,6-naphthyridine derivative sophalode K **38** (Figure 12) decreased significantly the secretion of enzymes playing crucial role in development of inflammation: iNOS (inducible nitric oxide synthase) and COX-2 (cyclooxygenase 2).




Figure 12. Structures of 5,6-dehydrolupanine **37** and sophalode K **38**.

Fan et al. [58] obtained five novel 1,6-naphthyridine alkaloid dimers, alopecuroides A–E **39–43** (Figure 13), from the aerial parts of *Sophora alopecuroides*. The study revealed strong anti-inflammatory properties of alopecuroides B **40** and C **41**. TNF- $\alpha$  and IL-6 levels were, respectively, 50.05% and 52.87% for alopecuroides B **35b** and 49.59% and 73.90% for alopecuroides C **41** in LPS-induced RAW 264.7 cells [58].

*Sophora* alkaloids were also reported to exhibit immunosuppressive properties. Alopecines A–E **44–48** (Figure 14), isolated from the seeds of *Sophora alopecuroides*, were assessed toward inhibiting proliferation of Concanavalin A-induced T lymphocytes and LPS-induced B cells [59]. Alopecine D **47** exerted the most potent effect, with  $IC_{50}$  = 3.98  $\mu$ M for inhibiting proliferation of T lymphocytes and 3.74  $\mu$ M for B lymphocytes (SI ratios respectively 8.0 and 8.5).

Pan et al. [60] evaluated antiviral activity of 16 natural alkaloids, obtained from rhizomes of *Sophora tonkinensis*. 12 $\alpha$ -Hydroxysophocarpine **49** (Figure 15), 12 $\beta$ -hydroxyso-phocarpine **50**, and sophoranol **52** inhibited Influenza Virus A/Hanfang/359/95 replication with  $IC_{50}$  values in the range of 63.07–242.46  $\mu$ M (SI ratios 3.1–5.7). 12 $\beta$ -Hydroxyoxyso-phocarpine **50**, 9 $\alpha$ -hydroxysophocarpine **51**, sophoranol **52**, and 14 $\beta$ -hydroxymatrine **53** (Figure 15) exerted the most potent activity against Coxsackie Virus B3 with  $IC_{50}$  values in the range of 26.62–252.18  $\mu$ M (SI ratios 3.0–6.8) [60].




Figure 13. Alopecuroides A–E 39–43.




Figure 14. Alopeccines A-E 44–48.





Figure 15. Structures of 12-hydroxyoxysophocarpine 49–50, 9 $\alpha$ -hydroxysophocarpine 51, sophoranol 52, and 14 $\beta$ -hydroxymatrine 53.

### 2.3. 1,7-Naphthyridine Derivatives

Bisleuconothine A 54 (Figure 16), determined as 1,7-naphthyridine alkaloid, was derived from the bark of *Leuconotis griffithii*—a species of plant with native distribution in southern Asia [61]. The agent 54 was shown to exert antineoplasm potency by inhibiting WNT signaling pathway, and to induce G0/G1 cell cycle arrest in cancer cells. It displayed significant antiproliferative properties against SW480, HCT116, HT29, and SW620 colon cancer cells in vitro (IC<sub>50</sub> values respectively 2.74, 3.18, 1.09, and 3.05  $\mu$ M), and reduced tumor growth in mice carrying HCT116 Xenograft [62]. Research conducted by

Wong et al. [63] in A549 non-small cell lung cancer and MCF-7 breast cancer cell lines showed that bisleuconothine A **54** owes its cytostatic properties to inducing autophagosome formation. Additionally, the compound **54** could also play a protective role in periodontitis. Bisleuconothine A **54** was determined to reduce RANKL expression and diminish periodontal tissue infiltration by pro-inflammatory polymorphonuclear cells [64].




**Figure 16.** Bisleuconothine A **54** and 1-N-methyl-3-methylamino-[N-butanoic acid-3-(9-methyl-8-propen-7-one)-amide]-benzo[f][1,7]naphthyridine-2-one **55**.

*Streptomyces albogriseolus* is a mangrove bacterium species, widely known for producing aminoglycoside antibiotics neomycin B and neomycin C. *Streptomyces albogriseolus* has also been reported to be the source of 1,7-naphthyridine compound, 1-N-methyl-3-methylamino-[N-butanoic acid-3-(9'-methyl-8'-propen-7'-one)-amide]-benzo[f][1,7]naphthyridine-2-one **55** (Figure 16) [65]. Cytotoxic evaluation performed by Tian et al. revealed that **55** displayed anticancer potency against HGC-27 human stomach carcinoma cell line [66].

#### 2.4. 2,6-Naphthyridine Derivatives

4-Methyl-2,6-naphthyridine **56** (Figure 17) is an alkaloid isolated from the dried plant of *Antirrhinum majus* by Harkiss and Swift in 1970 [67].



**Figure 17.** 4-Methyl-2,6-naphthyridine **56**.

Some indolo[2,6]naphthyridine alkaloids were obtained from plants of *Erythrina* spp. The seeds of these tropical trees contain erythrina alkaloids of varying degrees of toxicity. Some of them are used by indigenous peoples for medicinal purposes. They have an effect on the central nervous system and exhibit hypnotic, curare-like effects and neuromuscular inhibition, as well as sedative and hypotensive activity [68,69].

Erymelanthine-methyl(2*R*,13*bS*)-2-methoxy-2,6,8,9-tetrahydro-1*H*-indolo[7*a*,1*a*][2,6]naphthyridine-12-carboxylate **57** (Figure 18) was isolated from *Erythrina melanacantha* and *E. velutina* [70]. This alkaloid **57** was also obtained from *Erythrina merilliana* seeds by Jackson et al. [71]. Erymelanthine **57** was evaluated regarding its TRAIL (tumor necrosis

factor-related apoptosis-inducing ligand) enhanced activity, and this alkaloid showed no cytotoxicity [72].




Figure 18. Erymelanthine 57 and melanacanthine 58.

An example of Erythrina alkaloid containing indolo[2,6]naphthyridine scaffold is also 8-oxoerymelanthine 58, known as melanacanthine (methyl (2*R*,13*bS*)-2-methoxy-6-oxo-1,2,8,9-tetrahydroindolo[7*a*,1*a*][2,6]naphthyridine-12-carboxylate) 58 (Figure 18). This alkaloid 58 was isolated from *E. melanacantha* by Redha in 1983 [73]. Melanacanthine 58 inhibits thrombocyte agglutination and can be used in the treatment of hypertonia. The erythrina alkaloids 57–58 exhibited paralyzing activity [70,74].

Calycanthine 59 (Figure 19) was the first alkaloid isolated from the plants *Calycanthaceae* [75]. Calycanthine 59 was also isolated from *Meratia praecox* [76]. Toxic doses of calycanthine 59 cause excitation in mice, rats, and rabbits. After injection, calycanthine hydrochloride induces hyperglycaemia in rabbits and lowers blood pressure in cats or dogs [77]. Calycanthine 59 acts on peripheral motor nerves to cause muscle weakness associated in lower animals. In mammals, calycanthine causes seizures. The alkaloid 59 is also a strong depressant on the heart. It was reported that the anticonvulsant effect of calycanthine 59 is mainly caused by the inhibition of the release of the inhibitory neurotransmitter GABA (gamma-aminobutyric acid) [78].




Figure 19. Calycanthine 59, isocalycanthine 60, and calycanine 61.

Gordin [75] isolated a second alkaloid, isocalycanthine 60 (Figure 19), from the seeds of *Chimonanthus* genus. This tetrahydroisomer of calycanthine was also isolated from the leaves of *Psychotria colorata*, the plant used in folk medicine to relieve pain [79], and from *Psychotria forsteriana* [80].

Dibenzo[*c,h*][2,6]naphthyridine named calycanine 61 (Figure 19) was isolated from the seeds of *Chimonanthus praecox* [81]. This alkaloid 61 was also obtained by Zn dehydrogenation of calycanthine 59 [82]. Calycanthine 59 and calycanine 61 were evaluated for their antifungal activities. *Bipolaris maydis* was susceptible to calycanthine ( $EC_{50} = 29.3 \mu\text{g/mL}$ ) [83]. Calycanthine 59 was evaluated for its potent melanogenesis inhibitory activity, but showed cytotoxicity at  $10 \mu\text{M}$  [84].

### 2.5. 2,7-Naphthyridine Derivatives

Compounds containing the 2,7-naphthyridine scaffold were isolated from plants and various marine organisms. Naturally occurring bicyclic 2,7-naphthyridine derivatives are known as polycyclic compounds with the 2,7-naphthyridine ring in their structures.

#### 2.5.1. Bicyclic Alkaloids

Some of the monoterpene alkaloids of 2,7-naphthyridine structure were isolated from *Oleaceae* species [85]. Jasminine **62** (Figure 20) was obtained from the leaf of *Ligustrum novoguineense* by Hart et al. [86]. Jasminine **62** at a dose of 300 mg/kg causes a slight decrease in motor activity in mice. Cardiovascular activity of this alkaloid **62** was also evaluated, but it showed no significant effects [87].




Figure 20. Jasminine **62**, jasminidine **63**, and dihydrojasminine **64**.

Jasminidine **63** was isolated from *Syringa Vulgaris* [88], and dihydrojasminine **64** (Figure 20) was isolated from *Osmanthus austrocaledonica* [89,90].

Benkrief et al. [89] also isolated jasminine **62**, dihydrojasminine **64**, and a new coprine alkaloid—austrodimerine **65** (Figure 21) from *O. austrocaledonica*.




Figure 21. Austrodimerine **65**.

Powel et al. [91] reported antileukemic activity of extracts from seeds of *Sesbania drummondii*. Three years later, scientists described the isolation of alkaloid sesbanine—(3'*R*,4*R*)-3'-hydroxyspiro[2,7]naphthyridine-4,1'-cyclopentane-1,3-dione **66** (Figure 22) from the ethanol extract of *Sesbania drummondii* seeds, which are poisonous [92]. The extract containing sesbanine **66** showed cytotoxic activity (KB assay) and was active in vivo in the P-388 lymphocytic leukemia system [93].




Figure 22. Sesbanine **66**, 3-acetyl-2,7-naphthyridine **67**, and neozeylancine **68**.

3-Acetyl-2,7-naphthyridine **67** (Figure 22) was isolated by Janot et al. [94] from the roots and rhizomes of *Valeriana officinalis*. This compound **67** exhibited sedative and tranquilizer activity [94].

Neozeylancine **68** (Figure 22) was isolated in 1988 from *Neonauclea zeylanica* by Attar-Rahman [95].

Bioactive alkaloids Lophocladine A **69** and lophocladine B **70** (Figure 23) were isolated from the marine red alga *Lophocladia* sp. by Gross et al. [96]. 4-Phenyl-2,7-naphthyridin-1-one **69** exhibited antagonistic activity against  $\delta$ -opioid receptors, and 1-amino-4-phenyl-2,7-naphthyridine **70** showed cytotoxic activity against human lung tumor and breast cancer cell lines [96].





Figure 23. Structure of lophocladines **69–70**.

### 2.5.2. Tricyclic Alkaloids

Some alkaloids containing a diazaphenanthrene (benzo[2,7]naphthyridine) scaffold were discovered in some plants and marine organisms. 8-Bromo-4,5,5-trimethyl-5,6-dihydrobenzo[*c*][2,7]naphthyridine named Veranamine **71** (Figure 24) was isolated from the ethanol extract of the marine sponge *Verongula rigida*. Veranamine **71** had a moderate affinity for serotonin receptors and was therefore assessed for antidepressant activity in mice using the forced swim test. This alkaloid **71** showed antianxiety and antidepressant activity and selective affinity for 5HT<sub>2B</sub> and sigma-1 receptors [97].



**Figure 24.** Structures of benzo[2,7]naphthyridine alkaloids 71–74.

Alkaloids: 6-(3,4-dimethoxyphenyl)-3H-benzo[2,7]naphthyridin-6-ium-4-one called Perloline 72 and benzo[2,7]naphthyridin-4(3H)-one called perlolidine 73 (Figure 24) were isolated from the perennial rye grass *Lolium perenne* [98]. These alkaloids 72–73 inhibit in vitro cellulose digestion. Perloline 72 is slightly toxic after oral administration to mice and sheep [99].

Subarine-methyl 2-(5-oxo-6H-benzo[2,7]naphthyridin-4-yl)pyridine-3-carboxylate 74 (Figure 24) was isolated from Singaporean ascidian by Nilar et al. [100]. This marine alkaloid 74 was evaluated by in vitro screening against yeast and many Gram-positive and Gram-negative bacteria, but it exhibited no significant activity. Subarine 74 was also tested for in vitro cytotoxic activity on 60 human tumor cell lines, but did not show antiproliferative effect [101,102].

### 2.5.3. Tetracyclic Alkaloids

The extract of the plant *Alangium lamarckii* has been used by Indians to treat many human disorders [103]. In Thailand, it is useful in the treatment of asthma, coughs, hemorrhoids, diarrhea; and in India to treat leprosy, fever, or as an anthelmintic agent [104,105]. Pakrashi et al. [106,107] isolated tetracyclic alkaloids from the seeds of *A. lamarckii*. This alangium alkaloids namely: alamaridine 75, alangimaridine 76, dihydroalamarine 77, alangimarine 78, alamarine 79, alangimarine 80, isoalangimarine 81, isoalamarine 82, and dihydroisoalamarine 83 (Figure 25) contain the isoquino[2,1-b][2,7]naphthyridine scaffold [108,109].






Figure 25. Structures of alangium alkaloids 75–83.

Some tetracyclic alkaloids possess 2,7-naphthyridine ring in the structure of azaaporphine: eupomatidines 1–3 **84–86** and imbilines 1–3 **87–89** (Figure 26) were isolated from *Eupomatia bennettii* and *E. laurina* [110].




Figure 26. Eupomatidines 1–3 **84–86** and imbilines 1–3 **87–89**.

Kitahara et al. [111] synthesized eupomatidines 1–3 **84–86** and evaluated their antifungal activity against *Candida albicans*, *Paecilomyces variotii*, and *Trichophyton mentagrophytes*. Eupomatidine-1 **84** exhibited activity against those tree fungi with EC<sub>50</sub> values of 50 µg/mL, 6.25 µg/mL, and 0.4 µg/mL, respectively. Eupomatidine-2 **85** and eupomatidine-3 **86** were active only toward *T. mentagrophytes* with EC<sub>50</sub> values 3.1 µg/mL and 6.25 µg/mL, respectively. Khan et al. [112] evaluated eupomatidine-1 **84** against over a dozen Gram-positive and Gram-negative bacteria strains, a protozoan and nine fungi. This alkaloid **84** turned out to be much better than the applied standard (ketoconazole and griseofulvin), both in terms of scope and level of antifungal activity. Eupomatidine-1 **84** showed comparable antimicrobial activity to chloramphenicol.

Imbiline-1 **87** (Figure 26) was also isolated from a large tree *Duguetia hadrantha* and then evaluated for its antimalarial and antimicrobial activity [113]. Imbiline-1 **87** showed a weak antimalarial potency, but it was more active against chloroquine-resistant than chloroquine-sensitive *Plasmodium falciparum* clones. Imbiline-1 **87** was found to be inactive against *C. albicans*, *C. neoformans*, and *S. aureus*. This alkaloid **87** exhibited cytotoxic activity in vitro against human malignant melanoma and human ovary carcinoma cell lines with IC<sub>50</sub> values of 2 µg/mL and 5 µg/mL, respectively [113].

The scientists [113] isolated also new imbiline-type alkaloids: hadranthine A **90a** and hadranthine B **90b** from the ethanolic extract of *Duguetia hadrantha* (Figure 27).




Figure 27. Hadranthines A **90** and hadranthine B **91**, and sampangines **92–96**.

Hadranthine A (7,10-dimethoxy-6-methyl-4,5-dihydronaphthol[1,2,3-ij][2,7] naphthyridine-4,5-(6*H*)-dione) **90** showed in vitro antimalarial activity against chloroquine-resistant *P. falciparum* with IC<sub>50</sub> = 120 ng/mL. This alkaloid was active against *C. albicans* with MIC = 20 µg/mL. Hadranthine B (7-methoxy-4,5-dihydronaphthol[1,2,3-ij][2,7]naphthyridine-4,5-(6*H*)-dione) **91** did not show antimalarial activity, but it exhibited in vitro cytotoxic activity against human malignant melanoma, epidermoid carcinoma, ductal carcinoma, and ovary carcinoma cell lines with IC<sub>50</sub> values between 3–6 µg/mL [113]. This alkaloid **91** was also evaluated for its in vitro effects on immune response and inflammation, but did not show significant potency [113].

Sampangines **92–96** (Figure 27) also are tetracyclic alkaloids containing the 2,7-naphthyridine scaffold. Sampangine **92** was isolated first from the stem bark of plant *Cananga odorata* by Rao et al. [114]. 3-Methoxy derivative **93** was isolated from *Cleistopholis patens* by Liu et al. [115].

Sampangine **92** and 3-methoxysampangine **93** were also isolated from *Duguetia hadrantha* and then evaluated for their antimalarial, antifungal, and cytotoxic potency [115]. Both alkaloids **92–93** exhibited activity against *P. falciparum* with no cytotoxicity toward VERO cells. Sampangine **92** showed cytotoxicity to human malignant melanoma with IC<sub>50</sub> = 0.37 µg/mL and inhibited cell aggregation (MIC < 0.15 µg/mL) [113]. Sampangine **92** isolated from the stem bark of *Anaxagorea dolichocarpa* by Lucio et al. [116] demonstrated antitumor activity against human leukemic strains with IC<sub>50</sub> values of 10.15–11.80 µg/mL. Sampangine **92** and 11-methoxysampangine **94** isolated from the roots of *Ambavia gerardii* were evaluated for their antiproliferative activity [117]. Alkaloids **92** and **94** showed strong activity against human non-small cell lung cancer cell line with IC<sub>50</sub> values of 0.57–0.58 µM, but sampangine **92** was more active against human ovarian cancer cell line (IC<sub>50</sub> = 0.60 µM) than its 11-methoxy derivative **94** (IC<sub>50</sub> = 10.30 µM) [117]. Research by

scientists under Kluza [118] directions has shown that sampangine **92** induces apoptosis in HL-60 cells. In low concentrations, it caused G1 arrest and at the same time induced mitochondrial hyperpolarization. At higher concentrations, it elicited mitochondrial depolarization [118]. The treatment of human leukemia cells with sampangine **92** (40  $\mu\text{M}$ ) induced apoptosis due to an oxidative stress [119]. The ability of sampangine **92** to produce reactive oxygen species was confirmed by using an in vitro biochemical assay, and the participation of this alkaloid **92** in binding and damaging DNA was excluded [120].

Sampangine **92**, and two derivatives: 9-methoxysampangine **95** and 8,9-dimethoxysampangine **96**, were isolated from the barks of *Polyalthia nemoralis* [121] and evaluated for their cytotoxic activity. Obtained alkaloids **92**, **94**, **95** exhibited significant cytotoxicity against human carcinoma in the mouth, human breast cancer, human lung cancer, human hepatoma cancer, human prostate cancer, human ovarian adenocarcinoma, and human colon adenocarcinoma [121].


Sampangines **92–93** exhibited antimicrobial activity against *C. albicans*, *C. neoformans*, and *S. aureus* [113,122]. Sampangine **92** was found to be a strong antifungal agent against *Paecilomyces variotii*, and *Trichophyton mentagrophytes* with  $\text{EC}_{50} = 0.2 \mu\text{g}/\text{mL}$  [111]. Scientists reported that the antifungal activity of sampangine **92** may be due to perturbations in heme biosynthesis or metabolism [123].

3-Methoxysampangine **93** showed significant in vitro antifungal activity against *C. albicans* and *C. neoformans* and *A. fumigatus*, better than amphotericin B [115]. These alkaloids **92–93** also showed excellent antimycobacterial activity against *Mycobacterium intracellulare*, comparable to rifampin [124]. The dependence of the activity of sampangine derivatives **92–96** on the type of substituents in the naphtho[1,2,3-*ij*][2,7]naphthyridine scaffold is presented in Table 1.

**Table 1.** The dependence of the activity of alkaloids **92–96** on the types of substituents.

Activity	Substituents			
	R	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>
anticancer	H	H, OCH <sub>3</sub>	H, OCH <sub>3</sub>	H, OCH <sub>3</sub>
antimalarial	H, CH <sub>3</sub>	H	H	H
antifungal	H, CH <sub>3</sub>	H	H	H
antibacterial	H, CH <sub>3</sub>	H	H	H

Eupolauridines are tetracyclic alkaloids containing the 2,7-naphthyridine scaffold condensed with an indene ring (Figure 28).




**Figure 28.** Structures of eupolauridine analogs **97–101**.

Eupolauridine (indeno[1,2,3-*ij*][2,7]naphthyridine) **97** was isolated from *Cananga odorata* [125] and from *Eupomatia laurina* [126]. Pan et al. [117] isolated eupolauridine **97**, 8-hydroxyeupolauridine **98**, 9-methoxyeupolauridine-1-oxide **100**, and eupolauridine *N*-oxide **101** from *Ambavia gerrardii*. Alkaloids were screened for their in vitro antiproliferative activity. Among eupolauridine analogues, compound **101** was the most active against

human ovarian cancer cell line with  $IC_{50} = 3.5 \mu M$ , and only this derivative **101** showed antitumor activity against non-small-cell lung cancer cell line ( $IC_{50} = 1.77 \mu M$ ) [117]. 7-Methoxy-8-hydroxyeupolauridine **99** isolated from *Polyalthia nemoralis* by Oanh et al. [121] did not show cytotoxicity against seven tested cancer cell lines (human carcinoma in the mouth, human breast cancer, human lung cancer, human hepatoma cancer, human prostate cancer, human ovarian adenocarcinoma, and human colon adenocarcinoma). Eupolauridine **97** extracted from the root bark of *Cleistopholis patens* by Hufford et al. [127] exhibited a significant activity against *C. albicans* with MIC = 1.56  $\mu g/mL$ .

#### 2.5.4. Pentacyclic Alkaloids


Pentacyclic derivatives of indolo[2'3':3,4]pyrido[1,2-b][2,7]naphthyridine (Figure 29) were isolated from different plants. Alkaloids: nauclefine **102**, naucletine **103**, angustine **105**, angustoline **106**, and angustidine **107** isolated from *Neuclea officinalis* [128], and neonaucleine **104** and cadamine **109** isolated from *Ochreinauclea maingayii* exhibited potent vasorelaxant activity on isolated rat aorta [129]. Neuclefine **102** isolated from the bark of *Nauclea subdita* also induced apoptosis of diverse cancer cells and inhibited tumor xenograft growth [130]. Normalindine **111** and norisomalindine **110** were isolated from *Strychnos johnsonii* [131]. Isomalindine **113** and normalindine **111** were isolated from *Ophiorrhiza* sp. [132]. 19-O-ethylangustoline **99** and other alkaloids were isolated from the stem bark of *Sarcocephalus latifolius* [133]. Malindine **112** and isomalindine **113** were isolated from the stem bark of *Strychnos usambarensis* [134].



**Figure 29.** Structures of indolo[2'3':3,4]pyrido[1,2-b][2,7]naphthyridine derivatives **102–113**.


#### 2.5.5. Polycyclic Alkaloids—Pyridoacridine Analogs

Pyridoacridines are polyheterocyclic compounds containing pyrido[4,3,2-*mm*]acridine skeleton (Figure 30) and are a large number of marine-derived alkaloids.

pyrido[4,3,2-*mn*]acridine**Figure 30.** Structure of pyrido[4,3,2-*mn*]acridine.

Pyridoacridine alkaloids possess 2,7-naphthyridine scaffold in their structures and can be classified into tetracyclic, pentacyclic, hexacyclic, heptacyclic, and octacyclic compounds due to the number of rings attached to the pyrido[4,3,2-*mn*]acridine skeleton.

Calliactine **114** (Figure 31) was the first pyridoacridine derivative that was obtained. This alkaloid **114** was isolated from the sea anemone *Calliactis parasitica* in 1940 by E. Lederer et al. [135].


**Figure 31.** Calliactine **114**.

Since then, about a 100 pyridoacridine analogs have been found in many marine organisms. They have been isolated from ascidians, sponges, anemone, and certain mollusks. Most pyridoacridine derivatives were reported to possess significant pharmacological activities, including anticancer, antimicrobial, and antiparasitic activities [136–139].

#### Tetracyclic Pyridoacridine Derivatives

The first tetracyclic members of pyridoacridines were cystodytines **115–125** (Figure 32). These alkaloids **115–125** were isolated from the yellow tunicate *Cystodytes dellechiajei* by Kobayashi et al. [140,141]. Cystodytines A–K **115–125** were found to be cytotoxic. Cystodytine A–C **115–117** showed in vitro potent cytotoxicity against mouse leukemia cell lines with  $IC_{50}$  values of 0.22–0.24  $\mu\text{g}/\text{mL}$  [140] and Cystodytines D–I **118–123** against murine lymphoma and human epidermoid carcinoma KB cells with  $IC_{50}$  values of 0.068–1.4  $\mu\text{g}/\text{mL}$  [141]. Cystodytine J **124** isolated from *Cystodytes* sp. exhibited cytotoxic activity in vitro against the human colon tumor cell line with  $IC_{50} = 1.6 \mu\text{M}$  and inhibited the topoisomerase II with  $IC_{50} = 8.4 \mu\text{M}$ . The DNA binding ability of Cystodytine J **124** has also been reported [142]. 12-Methoxy derivatives **125** of cystodytine J were isolated from the ascidian *Lissoclinum notti*. Cystodytine K **125** showed cytotoxic activity in vitro against a murine leukemia cell line ( $IC_{50} = 1.3 \mu\text{M}$ ) [143].

Styelsamines A–D **126–129** (Figure 33) were isolated from the ascidian *Eusynstyela latericius* [144]. Obtained alkaloids **126–129** showed cytotoxicity toward the human colon tumor cell line with  $IC_{50}$  values of 33, 89, 2.6, and 1.6  $\mu\text{M}$ , respectively [144]. Styelsamines C **129** and D **128** were also isolated from the purple morph of the ascidian *Cystodytes dellechiajei* [145].



- 115)** R = H, R<sup>1</sup> = COCH(CH<sub>3</sub>)<sub>2</sub>  
**116)** R = H, R<sup>1</sup> = COC(CH<sub>3</sub>)CHCH<sub>3</sub>  
**117)** R = H, R<sup>1</sup> = COCH<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>OH  
**118)** R = OH, R<sup>1</sup> = COCH(CH<sub>3</sub>)<sub>2</sub>  
**119)** R = OH, R<sup>1</sup> = COC(CH<sub>3</sub>)CHCH<sub>3</sub>  
**120)** R = OCH<sub>3</sub>, R<sup>1</sup> = COCH(CH<sub>3</sub>)<sub>2</sub>  
**121)** R = OCH<sub>3</sub>, R<sup>1</sup> = COC(CH<sub>3</sub>)CHCH<sub>3</sub>  
**122)** R = OC(CH<sub>2</sub>)<sub>7</sub>CH=CH(CH<sub>2</sub>)<sub>7</sub>CH<sub>3</sub>, R<sup>1</sup> = COCH(CH<sub>3</sub>)<sub>2</sub>  
**123)** R = OC(CH<sub>2</sub>)<sub>7</sub>CH=CH(CH<sub>2</sub>)<sub>7</sub>CH<sub>3</sub>, R<sup>1</sup> = COC(CH<sub>3</sub>)CHCH<sub>3</sub>  
**124)** R = H, R<sup>1</sup> = COCH<sub>3</sub>  
**125)** R = OCH<sub>3</sub>, R<sup>1</sup> = COCH<sub>3</sub>

Figure 32. Cystodytines A–K 115–125.





Figure 33. Styelsamines A–D 126–129.

Fong and Copp [146] evaluated styelsamines **126–129** and cystodytines **115–125** for their DNA binding affinity and cytotoxic activity towards a panel of human tumor cell lines. Tested compounds showed moderate antiproliferative activity. Styelsamines **B 127** and **D 128** have particularly high affinity for calf thymus (CT)DNA, but cystodytines exhibited lower affinity [146].

Methylsulfanyl derivative of cystodytine **J** was isolated from the tunicate *Diplosoma* sp. by Charyulu et al. and named diplamine **130** [147]. Diplamine **130** and its isomer isodiplamine **131** (Figure 34) were also isolated from the ascidian *Lissoclinum notti* and were tested for their cytotoxicity against murine leukemia, human colon tumor, and non-malignant African Green Monkey kidney cell lines. Diplamine **130** was more cytotoxic towards BSC-1 cells than isodiplamine **131**. Diplamine **130** turned out to be a stronger topoisomerase II inhibitor than etoposide and showed the ability to intercalate into DNA [142].



**Figure 34.** Diplamines 130–132.


Diplamines **130–131** also exhibited moderate antimicrobial activity towards *Bacillus subtilis*, *Escherichia coli*, *Candida albicans*, and *Trichophyton mentagrophytes* [143]. Diplamine B **132** was isolated from the ascidian *Lissoclinum badium* and tested by immunoblotting for its effects on cellular p53 and Hdm2 in the tert-immortalized human retinal pigment epithelial cells (the potency was similar to proteasome inhibitor *N*-acetyl-leucyl-leucyl-norleucinal) [148].

The dependence of the activity of diplamine derivatives **130–132** on the type of substituents in the pyridoacridine scaffold is presented in Table 2.

**Table 2.** The dependence of the activity of alkaloids **130–132** on the type of substituents.

Activity	Substituent		
	R	R <sup>1</sup>	R <sup>2</sup>
anticancer	H, COCH <sub>3</sub>	SCH <sub>3</sub>	H
antimicrobial	COCH <sub>3</sub>	H, SCH <sub>3</sub>	H, SCH <sub>3</sub>

Another pyridoacridine alkaloid containing thiomethyl substituents—varamine A **133**, veramine B **134**, lissoclin A **135**, and lissoclin B **136** (Figure 35)—was isolated from the ascidian *Lissoclinum* sp. [149,150]. Varamines **133–134** showed cytotoxicity towards L-1210 murine leukemia cells with IC<sub>50</sub> values of 0.03 and 0.05 µg/mL, so they proved to be more toxic than cystoditines, which have the same skeleton but without the thiomethyl group [150].



**Figure 35.** Veramines **133**, **134** and lissoclins **135** and **136**.

Norsegoline **137** (Figure 36) was isolated from tunicate *Eudistoma* sp. [151,152]. Einat et al. [153] evaluated the inhibitory effect of norsegoline on the growth of myeloid progenitors obtained from bone marrow and peripheral blood of chronic myelogenous leukemia (CML) patients. Norsegoline **137** showed antiproliferative activity and may be

an effective agent for use in removing ex vivo Philadelphia-positive cells from peripheral blood of CML patients in conjunction with autologous bone marrow transplantation [153].




Figure 36. Norsesgoline **137** and Pantherinine **138**.

Kim et al. [154] isolated a brominated alkaloid pantherinine **138** (Figure 36) from the ascidian *Aplidium pantherinum*, which showed cytotoxic activity against murine leukemia cells ( $ED_{50} = 4.5 \mu\text{g/mL}$ ).

#### Penta- and Hexacyclic Pyridoacridine Derivatives

Lissoclinidine **139** (Figure 37) was isolated from the ascidian *Lissoclinum notti* [143]. This pentacyclic alkaloid **139** is a product of diplamine photoreduction, where the thiomethyl group is cyclised into a 1,3-oxathiolane ring. Lissoclinidine **139** showed moderate antiproliferative activity [143].




Figure 37. Lissoclinidines **139–140**.

Deacetyl derivative, lissoclinidine B **140**, was isolated from *Lissoclinum cf. badium* [155]. Lissoclinidine B **140** selectively induces cell apoptosis in a p53-dependent manner with  $IC_{50}$  values of  $98.1 \pm 6 \mu\text{M}$  and a dose-dependent increase in luciferase activity. The results of the studies showed that lissoclinidin B **140** is an inhibitor of Hdm2 auto-ubiquitylation and stabilizes p53 and Hdm2 in cells [148].

Kuanoniamine alkaloids **141–149** contain a thiazole ring fused to pyridoacridine scaffold (Figure 38). Kuanoniamines A–D **141–144** were first isolated from the mollusk *Chelynotus semperi* [156], and kuanoniamines E–F **145–146** were isolated by Nilar et al. [100] from Singaporean ascidians. *N*-Deacetylkuanoniamine C **147** was isolated from the Micronesian sponge *Oceanapia sp* [157]. Dehydrokuanoniamine B **148** and F **149** were isolated from South-Pacific Ocean ascidian *Cystodytes violatinctus* [158].






Figure 38. Kuanoniamines 141–149.

Cytotoxicity of kuanoniamines C **143** and D **144**, and *N*-deacetylkuanoniamine C **147** were studied *in vitro*, using two human cell lines (HeLa cells and MONO-MAC 6 cells) and exhibited similar activity with IC<sub>50</sub> values of 1.2–2.0 µg/mL [157].

Kuanoniamine D **144** exhibited affinity to A1- and A2A-adenosine receptors (K<sub>i</sub> values of 2.94 and 13.7 µM, respectively), and all derivatives showed moderate affinity to benzodiazepine binding sites of GABA-A receptors [157]. Dehydrokuanoniamine F **149** showed cytotoxic activity toward the SW480 colon cancer cell line with IC<sub>50</sub> values of 3.30 µM [158].

Sagitols are hydroxy analogs of kuanoniamines (Figure 39). Sagitol **150** and sagitol C **151** were isolated from the Indonesian sponge *Oceanapia* sp. [159,160]. Sagitol C **151** exhibited antiproliferative activity towards mouse lymphoma, human cervix carcinoma, and rats brain tumor cell lines in MTT (the microculture tetrazolium) assay [161]. Sagitol D **152** was isolated from Vietnamese ascidians and showed a weak antioxidant activity with IC<sub>50</sub> values of 92 µM in the DPPH (2,2-diphenyl-1-picryl-hydrazyl-hydrate) assay [160].




Figure 39. Sagitols 150–152.

Other pyridoacridine alkaloids containing a thiazole ring fused with pyridoacridine skeleton are Dercitin **153** isolated from *Dercitus* sp. sponges and its analogs isolated from *Stelletta* sp. sponges (Figure 40) [162–164]. Dercitin **153** exhibited *in vivo* antitumor activity. This alkaloid **153** inhibited the proliferation of murine leukemia and human leukemia, and lung, melanoma, and colon tumor cells with IC<sub>50</sub> values of 63–150 nM. Dercitin **153** was a potent inhibitor of DNA polymerase I and showed an effect on the stabilization of protein–DNA complexes [165]. Dercitine analogs: nordecitine **154**, dercitamide **155**, dercitamine **156**, cyclodercitine **157**, dehydrocyclodercitine **158**, and stellettamine **159** also showed antiproliferative activity, but were less potent than dercitine **153** (Table 3) [166].




Figure 40. Dercitin analogs 153–159.

Table 3. Antiproliferative activity of dercitine analogs 153–159.

Alkaloid	Activity	IC <sub>50</sub>
153	antiproliferative inhibition of polymerase I stabilization of protein-DNA complexes	63–150 nM
154	antiproliferative	4.8 μM
155	antiproliferative	26.7 μM
156	antiproliferative	12.0 μM
157	antiproliferative	1.9 μM
158	antiproliferative	9.9 μM
159	antiproliferative	60.0 μM

Sebastianine A **160** has a pyrrole ring and sebastianine B **161** has a pyrrolidine ring fused with the pyridoacridine scaffold (Figure 41). These alkaloids **160–161** were isolated from the ascidian *Cystodytes dellechiaiei* and showed cytotoxic activity against the HCT-116 colon carcinoma cells, indicating a p53-dependent mechanism [167].




Figure 41. Sebastianine A 160 and B 161.

Arnoamines **162–165** have a pyrrole ring fused to the pyridoacridine scaffold (Figure 42). These cytotoxic alkaloids **162–165** were isolated from the ascidian *Cystodytes* sp. [158,168]. Arnoamine A **162** showed good antitumor activity against breast cancer cell lines with  $GI_{50}$  value of 0.3  $\mu\text{g}/\text{mL}$  and weak activity against lung and colon cell lines with  $GI_{50}$  of 2.0 and 4.0  $\mu\text{g}/\text{mL}$ , respectively. Arnoamine B **163** exhibited weak antiproliferative activity against the same cancer cell lines ( $GI_{50}$  of 2.0–3.0  $\mu\text{g}/\text{mL}$ ) [168]. Cytotoxic activity of arnoamine C **164** and arnoamine D **165** were evaluated against melanoma and colon cancer cell lines. Arnoamine D **165** was found to be more active than arnoamine C **164** (with  $IC_{50}$  values of 4.32–8.48  $\mu\text{M}$ ) [158].




Figure 42. Arnoamines 162–165.

The first analog of pyridoacridine obtained from marine organisms was amphimedine **166**. This alkaloid **166** containing a pyridoquinoline skeleton was isolated from an *Amphimedon* sp. sponge [169]. Later, more amphimedine-type alkaloids (Figure 43) **166–178** were isolated from the marine sponge *Xestospongia* sp. and the ascidian *Cystodytes dellechiajei* [145,155].

Amphimedine analogs: amphimedine **166**, neoamphimedine **168**, deoxyamphimedine **170**, 1-hydroxy-deoxyamphimedine **171**, 3-hydroxy-deoxyamphimedine **172**, and debromopetrosamine **176** were evaluated in a zebrafish phenotype-based assay and only amphimedine **166** caused embryo necrosis, pericardial edema, and an enlarged yolk with a thin extension at 30  $\mu\text{M}$  [170]. Amphimedine **166** exhibited cytotoxic activity toward P388 murine leukemia cells, but it did not inhibit topoisomerase II [169,171,172]. Neoamphimedine **168** was cytotoxic toward normal CHOAA8 cells and deoxyamphimedine **170** against human colon tumor cells [173]. Neoamphimedine **168** also showed antitrypanosomal activity against *T. brucei* with  $IC_{50} = 0.21 \mu\text{M}$ , but amphimedine **166** was inactive [171,173]. Demethyldeoxyamphimedine **173** showed antibacterial activity against *L. anguillarum* and *M. luteus* [145].





Figure 43. Alkaloids 166–178.

The presence of a bromine atom on the benzene ring determines the activity of these derivatives (Table 4). Petrosamine **177** isolated from *Petrosia* sp. sponge was found to be about six times more potent an AChE inhibitor than galanthamine (IC<sub>50</sub> = 0.091 μM) [174]. Petrosamine B **178** weakly inhibited the *Helicobacter pylori* aspartyl semialdehyde dehydrogenase (IC<sub>50</sub> = 306 μM) [175].

**Table 4.** The dependence of the activity of petrosamine analogs 176–178 on the type of substituents.

Activity	Substituent	
	R	R <sup>1</sup>
AChE inhibitor	H	Br
antibacterial ( <i>H. pylori</i> )	Br	H
inactive	H	H

Asciddidemins also possess a pyridine ring fused to the pyridoacridine scaffold (Figure 44). Asciddidemins 179 was isolated from the tunicate *Didemnum* sp. and the ascidian *Cystodytes dellechiaiei* [155], and later with 12-deoxyasciddidemins 181 from the ascidian *Polysyncraton echinatum* [176]. These alkaloids 179 and 181 showed potent activity against *T. brucei* with IC<sub>50</sub> values of 0.077 and 0.032 μM, respectively [176]. Asciddidemins 179 also exhibited antimicrobial activity against *C. resinae*, *E. coli*, and *B. subtilis* [177], and very good potency against *M. tuberculosis* (MIC = 0.35 μM) [178]. Asciddidemins 179 causes release of calcium ions in the sarcoplasmic reticulum seven times more than caffeine [140]. Asciddidemins analogs showed cytotoxic activities. Asciddidemins 179 and 12-deoxyasciddidemins 181 exhibited cytotoxic activity toward the human embryonic kidney cell line with IC<sub>50</sub> values of 1.48 and 7.63 μM, respectively [176]. Asciddidemins 179 showed cytotoxic effects against murine leukemia cells (IC<sub>50</sub> = 0.39 μg/mL) [140]. 11-Hydroxyasciddidemins 180 showed cytotoxic activity against the human prostate cancer (PC3) cell line with IC<sub>50</sub> = 1.9 μM [179].

**Figure 44.** Structures of asciddidemins analogs 179–186.

Meridine **182** (Figure 44) isolated from the ascidian *Amphicarpa meridiana* [180] and from the marine sponge *Ecionemia geodides* [181] also showed cytotoxic activity against the invasive bladder cancer cell lines (IC<sub>50</sub> values of 3.76–4.56 μM) [181].

Ecionines A **183** and B **184** (Figure 44) possessing an imine moiety were isolated from *Ecionemia geodides* sponge [181]. Ecionine A **183** showed moderate cytotoxic activity against a panel of human bladder cancer cell lines with IC<sub>50</sub> values of 3–7 μM [181].

Ancorine **185** and cnemidine A **186** are analogs of hydroxyascididemes (Figure 44). Ancorine **185** was isolated from the sponge *Ancorina geodides*, and cnemidine A **186** was isolated from the tunicate *Cnemidocarpa stolonifera* [182]. Cnemidine A **186** selectively inhibited PC3 with IC<sub>50</sub> = 1.1 μM [182].

Shermilamines are alkaloids with the 3-thiomorpholinone ring fused to pyridoacridine scaffold (Figure 45). These alkaloids **187–190** were first isolated from the tunicate *Trididemnum* sp. [183,184], and later also from the ascidian *Cystodytes* sp. [142,185]. Shermilamines A **187** and B **188** exhibited cytotoxicity to murine leukemia cells. Shermilamine B **188** showed in vitro cytotoxic activity against KB cells with IC<sub>50</sub> = 5 μg/mL, and human colon tumor cells with IC<sub>50</sub> = 13.8 μM [156]. Shermilamines B and C **188–189** inhibit topoisomerase II and have the ability to intercalate into calf thymus DNA [142]. Shermilamine B **188** and *N*-deacetylshermilamine **190** were evaluated for their antibacterial activity against *E. coli* and *M. luteus*, but they were found to be less potent than reference gentamicin [138].





Figure 45. Shermilamines 187–190.

#### Hepta- and Oxacyclic Pyridoacridine Derivatives

Eilatin **191** is a symmetrical, heptacyclic alkaloid containing two pyridoacridine moieties (Figure 46). This alkaloid **191** was isolated from the tunicate *Eudistoma* sp. [151,152] and also from the ascidians *Cystodytes* sp. and *Polysyncraton echinatum* [142,169]. Eilatin **191** showed in vitro antiproliferative activity against the human colon tumor cell line and the human embryonic kidney cell line [176]. It also inhibited topoisomerase II and intercalated into DNA [142]. Eilatin **191** has two sets of nitrogen atoms capable of metal ion chelation. Complexes of eilatin–Ru(II) exhibited strong anti-HIV activity [186].

Biemnadin **192** is the octacyclic alkaloid containing the 2,7-naphthyridine ring in its skeleton (Figure 46). This alkaloid **192** was isolated from *Biemna* sp. sponges [187]. Biemnadin **192** showed weak cytotoxic activity toward the superficial bladder cancer cell line [181] and induced multipolar neuritogenesis [188].



**Figure 46.** Eilatin 191 and biemnadin 192.

### 2.6. Naphthyridines Molecular Mechanisms of Action—What Do We Know?

Naturally occurring naphthyridines are characterized by diverse mechanisms of action. Some of their biomolecular activities have been discovered, nevertheless there is still much to explore in this field.

Naphthyridines obtained from natural sources are characterized by anticancer potency. The compounds exhibit features of topoisomerase inhibitors and DNA intercalators [142]. They were documented to induce apoptosis in cancer cells in both p53-dependent and p53-independent manner [23,25,148,167]. Moreover, the compounds interfere with procytotoxic signaling pathways, i.e., AKT/mTOR, ERK, JNK, WNT [38–40,62]. Antineoplasm properties against drug-resistant tumors could be elucidated by inhibiting efflux-pumps activity, however, this topic requires further study [41,42].

Anti-inflammatory activity of naphthyridines is based on reducing iNOS and COX-2 release, decrease in NO production, and IL-6 and TNF- $\alpha$  secretion [7,15,54,56,57]. They suppress autoimmunity reactions through an IFN- $\beta$ /IL-27/IL-10 pathway, and by targeting proautoimmunity gene expression including angiogenin and stratifin [48,49].

The compounds modulate neurotransmission by affinity to GABA A and MAO A receptors, and inhibiting AchE activity [29,157,174].

Natural naphthyridines antiinfectious properties were widely screened against many infectious species [6,8,111,112,178]. However, molecular mechanisms of their action are still poorly researched and described. This issue is an interesting target for deeper research.

Natural naphthyridines have an extensive background of preliminary research, which is a solid foundation for molecular studies. Further investigations are still needed.

### 3. Conclusions

The natural environment, including marine and terrestrial organisms, should be considered as a rich source of bioactive substances. Naturally-derived naphthyridines, isolated mostly from sea species and terrestrial plants, have been shown as potent chemical compounds with multidirectional activity. Natural naphthyridines are most abundantly represented by 1,6- and 2,7-naphthyridine isomeric forms. Until now, research studies revealed their impressive antimicrobial [6,8,177], antifungal [6,8,111,112], and antimycobacterial [10,178] effects, and some of them displayed activity superior or comparable to those presented by chloramphenicol [112], amphotericin B [115], and rifampin [124]—drugs used in standard therapeutic regimens. Moreover, naphthyridines were shown to present significant properties including antiinfectious: antiviral [11,24,50,51], antiparasitic [9,176], and antimalarial [113]; anticancer [5,6,23,35]; influencing cardiovascular system: hypotensive [16,27], cardioprotective [43,44]; neurological: sedative [94], analgesic [15], anticonvulsant [78], stimulating neuritogenesis [188]; psychotropic: antianxiety [97], antidepressant [29,97]; and affecting immune system: anti-inflammatory [7,56,57], immunosuppressant [48–50]. The spectrum of activity of naturally-derived naphthyridines is wide, thus these compounds are undeniably fascinating subjects of research. An undoubted advantage of naphthyridines is their wide availability thanks to the possibility

of obtaining them both from natural sources and synthetically. The versatility of naphthyridines is expressed by the occurrence of multiple activities within a single compound. Moreover, many of the representatives are considered as safe and nontoxic, and constitute a great alternatives for standard therapies [9,48]. We strongly believe that this work will contribute to further exploration of naphthyridine derivatives—their natural sources and bioactive properties—and will result in the use of these chemical compounds for therapeutic purposes in the future.

**Author Contributions:** Conceptualization, G.C. and A.W.; investigation, G.C. and A.W.; writing—original draft preparation, G.C. and A.W.; writing—review and editing, G.C., A.W. and E.B.; visualization, G.C., E.B. and A.W.; supervision, E.B. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the Ministry of Health subvention according to the numbers SUB.D.130.19.040 and SUB.D140.21.113 from the IT Simple system of Wroclaw Medical University.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Hardy, K. Paleomedicine and the evolutionary context of medicinal plant use. *Rev. Bras. Farm.* **2021**, *31*, 1–15. [[CrossRef](#)] [[PubMed](#)]
2. Leshner, G.Y.; Froelich, E.J.; Gruett, M.D.; Bailey, J.H.; Brundage, R.P. 1,8-naphthyridine derivatives. A new class of chemotherapeutic agents. *J. Med. Chem.* **1962**, *5*, 1063–1065. [[CrossRef](#)]
3. Showalter, H.D.H. Progress in the synthesis of canthine alkaloids and ring-truncated congeners. *J. Nat. Prod.* **2012**, *76*, 455–467. [[CrossRef](#)] [[PubMed](#)]
4. Arunachalam, K.; Damazo, A.S.; Macho, A.; Machado, M.S.; Pavan, E.; Figueiredo, F.D.F.; Oliveira, D.M.; Duckworth, C.A.; Thangaraj, P.; Leonti, M.; et al. Canthin-6-one ameliorates TNBS-induced colitis in rats by modulating inflammation and oxidative stress. An in vivo and in silico approach. *Biochem. Pharmacol.* **2021**, *186*, 114490. [[CrossRef](#)]
5. Torquato, H.F.V.; Ribeiro-Filho, A.C.; Buri, M.; Júnior, R.T.A.; Pimenta, R.; de Oliveira, J.S.R.; Filho, V.O.; Macho, A.; Paredes-Gamero, E.J.; Martins, D.T.D.O. Canthin-6-one induces cell death, cell cycle arrest and differentiation in human myeloid leukemia cells. *Biochim. Biophys. Acta Gen. Subj.* **2017**, *1861*, 958–967. [[CrossRef](#)] [[PubMed](#)]
6. Kaigongi, M.M.; Lukhoba, C.W.; Yaouba, S.; Makunga, N.P.; Githiomi, J.; Yenesew, A. In vitro antimicrobial and antiproliferative activities of the root bark extract and isolated chemical constituents of *Zanthoxylum paracanthum* Kokwaro (Rutaceae). *Plants* **2020**, *9*, 920. [[CrossRef](#)] [[PubMed](#)]
7. Kim, H.M.; Lee, J.S.; Sezirahiga, J.; Kwon, J.; Jeong, M.; Lee, D.; Choi, J.-H.; Jang, D.S. A new canthinone-type alkaloid isolated from *Ailanthus altissima* swingle. *Molecules* **2016**, *21*, 642. [[CrossRef](#)]
8. Zhao, F.; Dai, J.-K.; Liu, D.; Wang, S.-J.; Wang, J.-R. Synthesis and evaluation of ester derivatives of 10-hydroxycanthin-6-one as potential antimicrobial agents. *Molecules* **2016**, *21*, 390. [[CrossRef](#)] [[PubMed](#)]
9. Ferreira, M.E.; Nakayama, H.; de Arias, A.R.; Schinini, A.; de Bilbao, N.V.; Serna, E.; Lagoutte, D.; Soriano-Agatón, F.; Poupon, E.; Hocquemiller, R.; et al. Effects of canthin-6-one alkaloids from *Zanthoxylum chiloperone* on trypanosoma cruzi-infected mice. *J. Ethnopharmacol.* **2007**, *109*, 258–263. [[CrossRef](#)]
10. O'Donnell, G.; Gibbons, S. Antibacterial activity of two canthin-6-one alkaloids from *Allium neapolitanum*. *Phytotherapy Res.* **2007**, *21*, 653–657. [[CrossRef](#)] [[PubMed](#)]
11. Xu, Z.; Chang, F.-R.; Wang, H.-K.; Kashiwada, Y.; McPhail, A.T.; Bastow, K.F.; Tachibana, Y.; Cosentino, M.; Lee, K.-H. Anti-HIV agents 451 and antitumor agents 205.2 two new sesquiterpenes, leitneridanins A and B, and the cytotoxic and anti-HIV principles from *Leitneria floridana*. *J. Nat. Prod.* **2000**, *63*, 1712–1715. [[CrossRef](#)]
12. Ammirante, M.; Di Giacomo, R.; De Martino, L.; Rosati, A.; Festa, M.; Gentilella, A.; Pascale, M.C.; Belisario, M.A.; Leone, A.; Turco, M.C.; et al. 1-methoxy-canthin-6-one induces c-Jun NH2-terminal kinase-dependent apoptosis and synergizes with tumor necrosis factor-related apoptosis-inducing ligand activity in human neoplastic cells of hematopoietic or endodermal origin. *Cancer Res.* **2006**, *66*, 4385–4393. [[CrossRef](#)] [[PubMed](#)]
13. Tran, T.V.A.; Malainer, C.; Schwaiger, S.; Atanasov, A.G.; Heiss, E.; Dirsch, V.M.; Stuppner, H. NF- $\kappa$ B inhibitors from *Eurycoma longifolia*. *J. Nat. Prod.* **2014**, *77*, 483–488. [[CrossRef](#)] [[PubMed](#)]
14. Tung, M.H.T.; Duc, H.V.; Huong, T.T.; Duong, N.T.; Phuong, D.T.; Thao, D.T.; Tai, B.H.; Kim, Y.H.; Bach, T.T.; Cuong, N.M. Cytotoxic compounds from *Brucea mollis*. *Sci. Pharm.* **2013**, *81*, 819–831. [[CrossRef](#)] [[PubMed](#)]
15. Jiao, W.-H.; Gao, H.; Zhao, F.; Lin, H.-W.; Pan, Y.-M.; Zhou, G.-X.; Yao, X.-S. Anti-inflammatory alkaloids from the stems of *Picrasma quassioides* Bennet. *Chem. Pharm. Bull.* **2011**, *59*, 359–364. [[CrossRef](#)] [[PubMed](#)]



16. Masdeu, C.; Fuertes, M.; Martin-Encinas, E.; Selas, A.; Rubiales, G.; Palacios, F.; Alonso, C. Fused 1,5-naphthyridines: Synthetic tools and applications. *Molecules* **2020**, *25*, 3508. [[CrossRef](#)]
17. Gray, J. Notes on the arrangement of sponges, with the descriptions of some new genera. *Proc. Zool. Soc. Lond.* **1867**, *1867*, 492–558.
18. He, Q.; Miao, S.; Ni, N.; Man, Y.; Gong, K. A review of the secondary metabolites from the marine sponges of the genus *Aaptos*. *Nat. Prod. Commun.* **2020**, *15*. [[CrossRef](#)]
19. Nakamura, H.; Kobayashi, J.; Ohizumi, Y.; Hirata, Y. Isolation and structure of aaptamine a novel heteroaromatic substance possessing  $\alpha$ -blocking activity from the sea sponge. *Tetrahedron Lett.* **1982**, *23*, 5555–5558. [[CrossRef](#)]
20. Gong, K.; Miao, S.; Yang, L.; Wu, Y.; Guo, J.; Chen, W.; Dai, J.; Du, J.; Xi, S. Aaptamine attenuates the proliferation and progression of non-small cell lung carcinoma. *Pharm. Biol.* **2020**, *58*, 1044–1054. [[CrossRef](#)]
21. Tsukamoto, S.; Yamanokuchi, R.; Yoshitomi, M.; Sato, K.; Ikeda, T.; Rotinsulu, H.; Mangindaan, R.E.; de Voogd, N.; van Soest, R.W.; Yokosawa, H. Aaptamine, an alkaloid from the sponge *Aaptos suberitoides*, functions as a proteasome inhibitor. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 3341–3343. [[CrossRef](#)] [[PubMed](#)]
22. Shaari, K.; Ling, K.C.; Rashid, Z.M.; Jean, T.P.; Abas, F.; Raof, S.M.; Zainal, Z.; Lajis, N.H.; Mohamad, H.; Ali, A.M. Cytotoxic aaptamines from Malaysian *Aaptos aaptos*. *Mar. Drugs* **2008**, *7*, 1–8. [[CrossRef](#)]
23. Li, Q.-L.; Zhang, P.-P.; Wang, P.-Q.; Yu, H.-B.; Sun, F.; Hu, W.-Z.; Wu, W.-H.; Zhang, X.; Chen, F.; Chu, Z.-Y.; et al. The cytotoxic and mechanistic effects of aaptamine on hepatocellular carcinoma. *Anti Cancer Agents Med. Chem.* **2015**, *15*, 291–297. [[CrossRef](#)]
24. Bowling, J.J.; Pennaka, H.K.; Ivey, K.; Wahyuono, S.; Kelly, M.; Schinazi, R.F.; Valeriote, F.A.; Graves, D.E.; Hamann, M.T. Antiviral and anticancer optimization studies of the DNA-binding marine natural product aaptamine. *Chem. Biol. Drug Des.* **2008**, *71*, 205–215. [[CrossRef](#)] [[PubMed](#)]
25. Aoki, S.; Kong, D.; Suna, H.; Sowa, Y.; Sakai, T.; Setiawan, A.; Kobayashi, M. Aaptamine, a spongean alkaloid, activates p21 promoter in a p53-independent manner. *Biochem. Biophys. Res. Commun.* **2006**, *342*, 101–106. [[CrossRef](#)] [[PubMed](#)]
26. Dyshlovoy, S.; Venz, S.; Shubina, L.K.; Fedorov, S.N.; Walther, R.; Jacobsen, C.; Stonik, V.A.; Bokemeyer, C.; Balabanov, S.; Honecker, F. Activity of aaptamine and two derivatives, demethyloxyaaptamine and iso-aaptamine, in cisplatin-resistant germ cell cancer. *J. Proteom.* **2014**, *96*, 223–239. [[CrossRef](#)]
27. Ohizumi, Y.; Kajiwara, A.; Nakamura, H.; Kobayashi, J.  $\alpha$ -Adrenoceptor blocking action of aaptamine, a novel marine natural product, in vascular smooth muscle. *J. Pharm. Pharmacol.* **2011**, *36*, 785–786. [[CrossRef](#)]
28. Amin, N.M.; Hamdin, M.S.; Amir, M.; Azarnudin, T.; Asari, A.; Nur, F.; Rashid, A.A.; Mariam, S.; Nor, M. Cytotoxicity effect of Aaptamine and its derivatives on *Acanthamoeba castellanii* (IMR isolate). *Sci. Int.* **2018**, *30*, 309–313.
29. Loffina, D.I.; Volkovitskaya, O.É.; Utkina, N.K.; Fedoreev, S.A. Aaptamine—New selective inhibitor of type A monoamine oxidase. *Pharm. Chem. J.* **1990**, *24*, 456–458.
30. Dyshlovoy, S.A.; Fedorov, S.N.; Shubina, L.K.; Kuzmich, A.S.; Bokemeyer, C.; Amsberg, G.K.-V.; Honecker, F. Aaptamines from the marine sponge *Aaptos* sp. Display anticancer activities in human cancer cell lines and modulate AP-1-, NF- $\kappa$ B-, and p53-dependent transcriptional activity in mouse JB6 Cl41 cells. *BioMed Res. Int.* **2014**, *8*, 469309. [[CrossRef](#)]
31. Wu, C.-F.; Lee, M.-G.; El-Shazly, M.; Lai, K.-H.; Ke, S.-C.; Su, C.-W.; Shih, S.-P.; Sung, P.-J.; Hong, M.-C.; Wen, Z.-H.; et al. Isoaaptamine induces T-47D cells apoptosis and autophagy via oxidative stress. *Mar. Drugs* **2018**, *16*, 18. [[CrossRef](#)]
32. Shubina, L.K.; Makarieva, T.N.; Dyshlovoy, S.; Fedorov, S.; Dmitrenok, P.S.; Stonik, V. Three new aaptamines from the marine sponge *Aaptos* sp. and their proapoptotic properties. *Nat. Prod. Commun.* **2010**, *5*, 1881–1884. [[CrossRef](#)]
33. Liu, C.; Tang, X.; Li, P.; Li, G. Suberitine A–D, Four new cytotoxic dimeric aaptamine alkaloids from the marine sponge *Aaptos suberitoides*. *Org. Lett.* **2012**, *14*, 1994–1997. [[CrossRef](#)] [[PubMed](#)]
34. Hamada, T.; Matsumoto, Y.; Phan, C.-S.; Kamada, T.; Onitsuka, S.; Okamura, H.; Iwagawa, T.; Arima, N.; Tani, F.; Vairappan, C.S. Aaptamine-related alkaloid from the marine sponge *Aaptos aaptos*. *Nat. Prod. Commun.* **2019**, *14*. [[CrossRef](#)]
35. Yu, H.-B.; Yang, F.; Sun, F.; Ma, G.-Y.; Gan, J.-H.; Hu, W.-Z.; Han, B.-N.; Jiao, W.-H.; Lin, H.-W. Cytotoxic aaptamine derivatives from the South China sea sponge *Aaptos aaptos*. *J. Nat. Prod.* **2014**, *77*, 2124–2129. [[CrossRef](#)]
36. Wang, P.; Huang, J.; Kurtán, T.; Mándi, A.; Jia, H.; Cheng, W.; Lin, W. Aaptodines A–D, Spiro naphthyridine–furooxazoloquinoline hybrid alkaloids from the sponge *Aaptos suberitoides*. *Org. Lett.* **2020**, *22*, 8215–8218. [[CrossRef](#)] [[PubMed](#)]
37. Aly, S.; Elissawy, A.M.; Eldahshan, O.A.; Elshanawany, M.A.; Efferth, T.; Singab, A.N.B. The pharmacology of the genus *Sophora* (Fabaceae): An updated review. *Phytomedicine* **2019**, *64*, 153070. [[CrossRef](#)] [[PubMed](#)]
38. Du, J.; Li, J.; Song, D.; Li, Q.; Li, L.; Li, B. Matrine exerts anti-breast cancer activity by mediating apoptosis and protective autophagy via the AKT/mTOR pathway in MCF-7 cells. *Mol. Med. Rep.* **2020**, *22*, 3659–3666. [[CrossRef](#)] [[PubMed](#)]
39. Wan, Q.; Du, Z.; Fang, Z.; Cheng, H.; Li, C.; Zhou, X. Matrine induces apoptosis and autophagy in human lung adenocarcinoma cells via upregulation of Cavin3 and suppression of PI3K/AKT pathway. *J. BUON* **2020**, *25*, 1512–1516.
40. Liang, X.; Ju, J. Matrine inhibits ovarian cancer cell viability and promotes apoptosis by regulating the ERK/JNK signaling pathway via p38MAPK. *Oncol. Rep.* **2021**, *45*, 1–10. [[CrossRef](#)]
41. Zhao, B.; Li, B.; Liu, Q.; Gao, F.; Zhang, Z.; Bai, H.; Wang, Y. Effects of matrine on the proliferation and apoptosis of vincristine-resistant retinoblastoma cells. *Exp. Ther. Med.* **2020**, *20*, 2838–2844. [[CrossRef](#)]
42. Chen, Z.; Nishimura, N.; Okamoto, T.; Wada, K.; Naora, K. Molecular mechanism of matrine from *Sophora alopecuroides* in the reversing effect of multi-anticancer drug resistance in K562/ADR cells. *BioMed Res. Int.* **2019**, *2019*, 1269532. [[CrossRef](#)]

43. Xiao, T.; Huang, J.; Liu, Y.; Zhao, Y.; Wei, M. Matrine protects cardiomyocytes against hyperglycemic stress by promoting mitofusin 2-induced mitochondrial fusion. *Front. Physiol.* **2021**, *11*, 597429. [[CrossRef](#)]
44. Liu, Y.; Liu, L.; Zhang, J. Protective role of matrine in sepsis-associated cardiac dysfunction through regulating the lncRNA PTENP1/miR-106b-5p axis. *Biomed. Pharmacother.* **2021**, *134*, 111112. [[CrossRef](#)] [[PubMed](#)]
45. Long, Y.; Lin, X.-T.; Zeng, K.-L.; Zhang, L. Efficacy of intramuscular matrine in the treatment of chronic hepatitis B. *Hepatobil. Pancreat. Dis. Int.* **2004**, *3*, 69–72.
46. Lao, Y. Clinical study on effect of matrine injection to protect the liver function for patients with primary hepatic carcinoma after trans-artery chemo-embolization (TAE). *J. Chin. Med. Mater.* **2005**, *28*, 637–638.
47. Xu, X.; Ling, Q.; Gao, F.; He, Z.-L.; Xie, H.-Y.; Zheng, S.-S. Hepatoprotective effects of marine and kuhuang in liver transplant recipients. *Am. J. Chin. Med.* **2009**, *37*, 27–34. [[CrossRef](#)]
48. Chu, Y.-J.; Ma, W.-D.; Thome, R.; Ping, J.-D.; Liu, F.-Z.; Wang, M.-R.; Zhang, M.-L.; Zhang, G.; Zhu, L. Matrine inhibits CNS autoimmunity through an IFN- $\beta$ -dependent mechanism. *Front. Immunol.* **2020**, *11*, 11. [[CrossRef](#)]
49. Dou, M.; Zhou, X.; Li, L.; Zhang, M.; Wang, W.; Wang, M.; Jing, Y.; Ma, R.; Zhao, J.; Zhu, L. Illumination of molecular pathways in multiple sclerosis lesions and the immune mechanism of matrine treatment in EAE, a mouse model of MS. *Front. Immunol.* **2021**, *12*, 1137. [[CrossRef](#)] [[PubMed](#)]
50. Sun, N.; Zhang, H.; Sun, P.; Khan, A.; Guo, J.; Zheng, X.; Sun, Y.; Fan, K.; Yin, W.; Li, H. Matrine exhibits antiviral activity in a PRRSV/PCV2 co-infected mouse model. *Phytomedicine* **2020**, *77*, 153289. [[CrossRef](#)] [[PubMed](#)]
51. Sun, N.; Sun, P.; Lv, H.; Sun, Y.; Guo, J.; Wang, Z.; Luo, T.; Wang, S.; Li, H. Matrine displayed antiviral activity in porcine alveolar macrophages co-infected by porcine reproductive and respiratory syndrome virus and porcine circovirus type. *Sci. Rep.* **2016**, *6*, 24401. [[CrossRef](#)]
52. Kianbakht, S.; Hajiaghaee, R.; Akhondzadeh, S. Efficacy and safety of *Sophora alopecuroides* var. *alopecuroides* seed extract for opioid detoxification: A randomized, double-blind, and placebo-controlled clinical trial. *Phytotherapy Res.* **2019**, *34*, 1108–1113. [[CrossRef](#)]
53. Lin, Z.; Huang, C.-F.; Liu, X.-S.; Jiang, J. In vitro anti-tumour activities of quinolizidine alkaloids derived from *Sophora flavescens* ait. *Basic Clin. Pharmacol. Toxicol.* **2010**, *108*, 304–309. [[CrossRef](#)] [[PubMed](#)]
54. Zhang, Y.; Wang, S.; Li, Y.; Xiao, Z.; Hu, Z.; Zhang, J. Sophocarpine and matrine inhibit the production of TNF- $\alpha$  and IL-6 in murine macrophages and prevent cachexia-related symptoms induced by colon26 adenocarcinoma in mice. *Int. Immunopharmacol.* **2008**, *8*, 1767–1772. [[CrossRef](#)] [[PubMed](#)]
55. Matsuda, K.; Yamada, K.; Kimura, M.; Hamada, M. Nematicidal activity of matrine and its derivatives against pine wood nematodes. *J. Agric. Food Chem.* **1991**, *39*, 189–191. [[CrossRef](#)]
56. Tang, Q.; Luo, D.; Lin, D.-C.; Wang, W.-Z.; Li, C.-J.; Zhuo, X.-F.; Wu, Z.-N.; Zhang, Y.-B.; Wang, G.-C.; Li, Y.-L. Five matrine-type alkaloids from *Sophora tonkinensis*. *J. Nat. Med.* **2021**, *75*, 682–687. [[CrossRef](#)] [[PubMed](#)]
57. Li, J.-C.; Dai, W.-F.; Liu, D.; Zhang, Z.-J.; Jiang, M.-Y.; Rao, K.-R.; Li, R.-T.; Li, H.-M. Quinolizidine alkaloids from *Sophora alopecuroides* with anti-inflammatory and anti-tumor properties. *Bioorg. Chem.* **2021**, *110*, 104781. [[CrossRef](#)]
58. Fan, C.-L.; Zhang, Y.-B.; Chen, Y.; Xie, P.; Wang, G.-C.; Tian, H.-Y.; Li, Y.-L.; Huang, X.-J.; Zhang, X.-Q.; Li, Z.-Y.; et al. Alopecuroides A–E, matrine-type alkaloid dimers from the aerial parts of *Sophora alopecuroides*. *J. Nat. Prod.* **2019**, *82*, 3227–3232. [[CrossRef](#)]
59. Wang, X.-F.; Zhu, Z.; Hao, T.-T.; Fang, Q.-Q.; Jiang, K.; Qu, S.-J.; Zuo, J.-P.; Zhu, W.; He, S.-J.; Tan, C.-H. Alopécines A–E, five chloro-containing matrine-type alkaloids with immunosuppressive activities from the seeds of *Sophora alopecuroides*. *Bioorg. Chem.* **2020**, *99*, 103812. [[CrossRef](#)]
60. Pan, Q.-M.; Li, Y.-H.; Hua, J.; Huang, F.-P.; Wang, H.-S.; Liang, D. Antiviral matrine-type alkaloids from the rhizomes of *Sophora tonkinensis*. *J. Nat. Prod.* **2015**, *78*, 1683–1688. [[CrossRef](#)]
61. Hirasawa, Y.; Shoji, T.; Arai, T.; Nugroho, A.E.; Deguchi, J.; Hosoya, T.; Uchiyama, N.; Goda, Y.; Awang, K.; Hadi, A.H.A.; et al. Bisleuconothine A, an eburnane–aspidosperma bisindole alkaloid from *Leuconotis griffithii*. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 2021–2024. [[CrossRef](#)] [[PubMed](#)]
62. Kong, L.-M.; Feng, T.; Wang, Y.-Y.; Li, X.-Y.; Ye, Z.; An, T.; Qing, C.; Luo, X.-D.; Li, Y. Bisleuconothine A, a bisindole alkaloid, inhibits colorectal cancer cell in vitro and in vivo targeting Wnt signaling. *Oncotarget* **2016**, *7*, 10203–10214. [[CrossRef](#)] [[PubMed](#)]
63. Wong, C.P.; Seki, A.; Horiguchi, K.; Shoji, T.; Arai, T.; Nugroho, A.E.; Hirasawa, Y.; Sato, F.; Kaneda, T.; Morita, H. Bisleuconothine A induces autophagosome formation by interfering with AKT-mTOR signaling pathway. *J. Nat. Prod.* **2015**, *78*, 1656–1662. [[CrossRef](#)] [[PubMed](#)]
64. Wang, F.; Sun, P.; Sun, Q. Bisleuconothine A protects periodontal tissue via the regulation of RANKL expression and infiltration of inflammatory cells. *Trop. J. Pharm. Res.* **2020**, *19*, 497–503. [[CrossRef](#)]
65. Li, X.-L.; Xu, M.-J.; Zhao, Y.-L.; Xu, J. A Novel Benzof[1,7]Naphthyridine Produced by Streptomyces Albogriseolus from Mangrove Sediments. *Molecules* **2010**, *15*, 9298–9307. [[CrossRef](#)] [[PubMed](#)]
66. Tian, C.; Jiao, X.; Liu, X.; Li, R.; Dong, L.; Liu, X.; Zhang, Z.; Xu, J.; Xu, M.; Xie, P. First total synthesis and determination of the absolute configuration of 1-N-methyl-3-methylamino-[N-butanoic acid-3-(9-methyl-8-propen-7-one)-amide]-benzof[1,7]naphthyridine-2-one, a novel benzo naphthyridine alkaloid. *Tetrahedron Lett.* **2012**, *53*, 4892–4895. [[CrossRef](#)]
67. Harkiss, K.; Swift, D. 4-methyl-2, 6-naphthyridine, a new plant constituent from *antirrhinum majus*. *Tetrahedron Lett.* **1970**, *11*, 4773–4774. [[CrossRef](#)]

68. Padwa, A.; Hennig, R.; Kappe, A.C.O.; Reger, T.S. A triple cascade sequence as a strategy for the construction of the erythrinane skeleton. *J. Org. Chem.* **1998**, *63*, 1144–1155. [[CrossRef](#)]
69. Tsuda, Y.; Sano, T. Chapter 4 erythrina and related Alkaloids. In *Alkaloids: Chemistry and Pharmacology*; Academic Press Inc.: Cambridge, MA, USA, 1996.
70. Dagne, E.; Steglich, W. Erymelanthine, a new type of erythrina alkaloid containing a 16-azaerythrinane skeleton. *Tetrahedron Lett.* **1983**, *24*, 5067–5070. [[CrossRef](#)]
71. Jackson, A.H. *The Chemistry and Biology of Isoquinoline Alkaloids*; Phillipson, J.D., Roberts, M.F., Zenk, M.H., Eds.; Springer: Berlin, Germany, 1985; p. 75.
72. Ozawa, M.; Etoh, T.; Hayashi, M.; Komiyama, K.; Kishida, A.; Ohsaki, A. TRAIL-enhancing activity of erythrinan alkaloids from *Erythrina velutina*. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 234–236. [[CrossRef](#)] [[PubMed](#)]
73. Redha, F.J.M. Chromatographic and Spectroscopic Studies of Erythrina Alkaloids. Ph.D. Thesis, University of Wales Cardiff, Cardiff, UK, 1983.
74. Chawla, A.S.; Kapoor, V.K. Erythrina Alkaloids. *Alkaloids Chem. Biol. Perspect.* **1995**, *9*, 85–153. [[CrossRef](#)]
75. Gordin, H.M. On the crystalline alkaloid of calycanthus glaucus. Third paper—On isocalycanthine, isomeric with calycanthine. *J. Am. Chem. Soc.* **1909**, *31*, 1305–1312. [[CrossRef](#)]
76. Manske, R.H.F. Calycanthine I. the isolation of calycanthine from *meratia praecox*. *J. Am. Chem. Soc.* **1929**, *51*, 1836–1839. [[CrossRef](#)]
77. Chen, A.L.; Powell, C.E.; Chen, K.K. The action of calycanthine. *J. Am. Pharm. Assoc.* **1942**, *31*, 513–516. [[CrossRef](#)]
78. Chebib, M. Convulsant actions of calycanthine. *Toxicol. Appl. Pharmacol.* **2003**, *190*, 58–64. [[CrossRef](#)]
79. Verotta, L.; Pilati, T.; Tatò, M.; Elisabetsky, E.; Amador, T.A.; Nunes, D.S. Pyrrolidinoindoline alkaloids from *Psychotria colorata*. *J. Nat. Prod.* **1998**, *61*, 392–396. [[CrossRef](#)]
80. Adjibade, Y.; Weniger, B.; Quirion, J.C.; Kuballa, B.; Cabalion, P.; Anton, R. Dimeric alkaloids from *Psychotria forsteriana*. *Phytochemistry* **1992**, *31*, 317–319. [[CrossRef](#)]
81. Kitajima, M.; Mori, I.; Arai, K.; Kogure, N.; Takayama, H. Two new tryptamine-derived alkaloids from *Chimonanthus praecox* f. *concolor*. *Tetrahedron Lett.* **2006**, *47*, 3199–3202. [[CrossRef](#)]
82. Woodward, R.B.; Yang, N.C.; Katz, T.J.; Clark, V.M.; Harley-Mason, J.; Ingleby, R.F.J. Calycanthine: The structure of the alkaloid and its degradation product, calycanine. *Proc. Chem. Soc.* **1960**, *2*, 76–78.
83. Zhang, J.-W.; Gao, J.-M.; Xu, T.; Zhang, X.-C.; Ma, Y.-T.; Jarussophon, S.; Konishi, Y. Antifungal activity of alkaloids from the seeds of *Chimonanthus praecox*. *Chem. Biodivers.* **2009**, *6*, 838–845. [[CrossRef](#)] [[PubMed](#)]
84. Morikawa, T.; Nakanishi, Y.; Ninomiya, K.; Matsuda, H.; Nakashima, S.; Miki, H.; Miyashita, Y.; Yoshikawa, M.; Hayakawa, T.; Muraoka, O. Dimeric pyrrolidinoindoline-type alkaloids with melanogenesis inhibitory activity in flower buds of *Chimonanthus praecox*. *J. Nat. Med.* **2014**, *68*, 539–549. [[CrossRef](#)] [[PubMed](#)]
85. Bannasar, M.-L.; Roca, T.; Zulaica, E.; Monerris, M. Total synthesis of the naphthyridine alkaloid jasminine. *Tetrahedron* **2004**, *60*, 6785–6789. [[CrossRef](#)]
86. Hart, N.K.; Johns, S.R.; Lamberton, J.A. The isolation of the alkaloid jasminixine from *Olea paniculata* (Oleaceae). *Aust. J. Chem.* **1971**, *24*, 1739–1740. [[CrossRef](#)]
87. Collins, D.J.; Culvenor, C.C.J.; Lamberton, J.A.; Loder, J.W.; Price, J.R. *Plants for Medicines: A Chemical and Pharmacological Survey of Plants in the Australian Region*; CSIRO Australia: Melbourne, Australia, 1990.
88. Ripperger, H. Jasminidin, ein neues monoterpene alkaloid aus *Syringa vulgaris*. *Phytochemistry* **1978**, *17*, 1069. [[CrossRef](#)]
89. Benkrief, R.; Ranarivelo, Y.; Skaltsounis, A.-L.; Tillequin, F.; Koch, M.; Pusset, J.; Sévenet, T. Monoterpene alkaloids, iridoids and phenylpropanoid glycosides from *Osmanthus austrocaledonica*. *Phytochemistry* **1998**, *47*, 825–832. [[CrossRef](#)]
90. Tiwara, K.P.; Minocha, P.K.; Masood, M.A. Closely related alkaloid, acanthicifoline, was isolated from *Acanthus ilicifolius* (Acanthaceae). *Pol. J. Chem.* **1980**, *54*, 857–858.
91. Powell, R.G.; Smith, C.R.; Madrigal, R.V. Antitumor activity of *Sesbania vesicaria*, *S. punicea*, and *S. drummondii* seed extracts. *Planta Med.* **1976**, *30*, 1–8. [[CrossRef](#)] [[PubMed](#)]
92. Powell, R.G.; Smith, C.R.; Weisleder, D.; Muthard, D.A.; Clardy, J. Sesbanine, a novel cytotoxic alkaloid from *Sesbania drummondii*. *J. Am. Chem. Soc.* **1979**, *101*, 2784–2785. [[CrossRef](#)]
93. Powell, R.G.; Smith, C.R., Jr. An investigation of the antitumor activity of *Sesbania drummondii*. *J. Nat. Prod.* **1981**, *44*, 86–90. [[CrossRef](#)]
94. Janot, M.M.; Guilhem, J.; Contz, O.; Venera, E. Contribution to the study of valerian alkaloids (*Valeriana officinalis*, L.): Actinidine and naphthyridylmethylketone, a new alkaloid. *Ann. Pharm. Fr.* **1979**, *37*, 413–420.
95. Rahman, A.; Vohra, I.I.; Choudhary, M.I.; de Silva, L.B.; Herath, W.H.M.W.; Navaratne, K.M. Neozeylanicine: A novel alkaloid from the timber of *Neonauclea zeylanica*. *Planta Med.* **1988**, *54*, 461–462.
96. Gross, H.; Goeger, D.E.; Hills, P.; Mooberry, S.L.; Ballantine, D.L.; Murray, T.F.; Valeriate, F.A.; Gerwick, W.H. Lophocladines, bioactive alkaloids from the red *Alga lophocladia* sp. *J. Nat. Prod.* **2006**, *69*, 640–644. [[CrossRef](#)] [[PubMed](#)]
97. Kochanowska-Karamyan, A.J.; Araujo, H.C.; Zhang, X.; El-Alfy, A.; Carvalho, P.; Avery, M.A.; Holmbo, S.D.; Magolan, J.; Hamann, M.T. Isolation and synthesis of veranamine, an antidepressant lead from the marine sponge *Verongula rigida*. *J. Nat. Prod.* **2020**, *83*, 1092–1098. [[CrossRef](#)] [[PubMed](#)]

98. Reifer, I.; White, E.P. Studies on perloline; Perlolidine and some fluorescent derivatives of perloline. *N. Z. J. Sci. Technol. B Gen. Sect.* **1945**, *27*, 242–247.
99. Rizk, A.-F. *Poisonous Plant Contamination of Edible Plants*; CRC Press: Boca Raton, FL, USA, 1990.
100. Nilar, N.; Sidebottom, P.J.; Carté, B.K.; Butler, M.S. Three new pyridoacridine type alkaloids from a *Singaporean ascidian*. *J. Nat. Prod.* **2002**, *65*, 1198–1200. [[CrossRef](#)] [[PubMed](#)]
101. Lotter, M. Short total synthesis of the marine alkaloid subarine. *Sci. Pharm.* **2009**, *77*, 1–7. [[CrossRef](#)]
102. Bijere, L.; Legentil, L.; Bastide, J.; Darro, F.; Rochart, C.; Delfourne, E. A total synthesis of subarine, a marine alkaloid related to the pyridoacridine family. *Eur. J. Org. Chem.* **2004**, *2004*, 1891–1893. [[CrossRef](#)]
103. Chopra, R.N.; Nayar, S.L.; Chopra, I.C. *Glossary of Indian Medicinal Plants*; Council of Scientific & Industrial Research: East Lansing, MI, USA, 1956.
104. Shrivastava, S.; Vinod, B.N.; Sunil, C. Pharmacological and phytochemical studies of *Alangium salvifolium* Wang.—A review. *Bull. Fac. Pharm. Cairo Univ.* **2017**, *55*, 217–222. [[CrossRef](#)]
105. Wiart, C. *Lead Compounds from Medicinal Plants for the Treatment of Cancer*; Academic Press Inc.: Cambridge, MA, USA, 2012.
106. Pakrashi, S.; Achari, B.; Ali, E.; Dastidar, P.G.; Sinha, R. Novel benzopyridoquinolizine bases from *Alangium lamarckii* Thw. *Tetrahedron Lett.* **1980**, *21*, 2667–2670. [[CrossRef](#)]
107. Jahangir; Brook, M.A.; MacLean, D.B.; Holland, H.L. 8H-Isoquino[2,1-*b*][2,7]naphthyridin-8-ones: Synthesis of the alangium alkaloids, alangimaridine and alangimarine. *Can. J. Chem.* **1987**, *65*, 2362–2368. [[CrossRef](#)]
108. Jahangir; Maclean, D.B.; Holland, H.L. Preparation of 8-methylberberines and Aza analogues: Synthesis of alamaridine. *Can. J. Chem.* **1987**, *65*, 727–733. [[CrossRef](#)]
109. Bhattacharjya, A.; Mukhopadhyay, R.; Pakrashi, S. Structure and synthesis of alamaridine, a novel benzopyridoquinolizine alkaloid from *Alangium lamarck* II. *Tetrahedron Lett.* **1986**, *27*, 1215–1216. [[CrossRef](#)]
110. Carroll, A.; Taylor, W.; Carroll, A. Constituents of eupomatia species. XIII. The structures of new lignans From the tubers and aerial parts of *Eupomatia bennettii*. *Aust. J. Chem.* **1991**, *44*, 1627–1633. [[CrossRef](#)]
111. Kitahara, Y.; Onikura, H.; Shibano, Y.; Watanabe, S.; Mikami, Y.; Kubo, A. Synthesis of eupomatidines 1, 2 and 3 and related compounds including amino-quinoline-quinone structure. *Tetrahedron* **1997**, *53*, 6001–6010. [[CrossRef](#)]
112. Khan, M.; Kihara, M.; Omoloso, A. Antimicrobial activity of the alkaloidal constituents of the root bark of *Eupomatia laurina*. *Pharm. Biol.* **2003**, *41*, 277–280. [[CrossRef](#)]
113. Muhammad, I.; Dunbar, D.C.; Takamatsu, S.; Walker, L.A.; Clark, A.M. Antimalarial, cytotoxic, and antifungal alkaloids from *Duguetia hadrantha*. *J. Nat. Prod.* **2001**, *64*, 559–562. [[CrossRef](#)] [[PubMed](#)]
114. Rao, J.U.M.; Giri, G.S.; Hanumaiah, T.; Rao, K.V.J. Sampangine, a New Alkaloid from *Cananga odorata*. *J. Nat. Prod.* **1986**, *49*, 346–347. [[CrossRef](#)]
115. Liu, S.C.; Oguntimein, B.; Hufford, C.D.; Clark, A.M. 3-Methoxysampangine, a novel antifungal copyrine alkaloid from *Cleistopholis patens*. *Antimicrob. Agents Chemother.* **1990**, *34*, 529–533. [[CrossRef](#)] [[PubMed](#)]
116. Lúcio, A.S.S.C.; Almeida, J.R.G.D.S.; Barbosa-Filho, J.M.; Pita, J.C.L.R.; Branco, M.V.S.C.; Diniz, M.D.F.F.M.; Agra, M.D.F.; Da-Cunha, E.V.; da Silva, M.S.; Tavares, J.F. Azaphenanthrene alkaloids with antitumoral activity from *Anaxagorea dolichocarpa* sprague & sandwith (Annonaceae). *Molecules* **2011**, *16*, 7125–7131. [[CrossRef](#)]
117. Pan, E.; Cao, S.; Brodie, P.J.; Callmander, M.W.; Randrianaivo, R.; Rakotonandrasana, S.; Rakotobe, E.; Rasamison, V.E.; TenDyke, K.; Shen, Y.; et al. Isolation and synthesis of antiproliferative eupolauridine alkaloids of *Ambavia gerrardiifrom* the madagascar dry forest(1). *J. Nat. Prod.* **2011**, *74*, 1169–1174. [[CrossRef](#)] [[PubMed](#)]
118. Kluza, J.; Clark, A.M.; Bailly, C. Apoptosis induced by the alkaloid sampangine in HL-60 leukemia cells: Correlation between the effects on the cell cycle progression and changes of mitochondrial potential. *Ann. N. Y. Acad. Sci.* **2003**, *1010*, 331–334. [[CrossRef](#)]
119. Kluza, J.; Mazinghien, R.; Degardin, K.; Lansiaux, A.; Bailly, C. Induction of apoptosis by the plant alkaloid sampangine in human HL-60 leukemia cells is mediated by reactive oxygen species. *Eur. J. Pharmacol.* **2005**, *525*, 32–40. [[CrossRef](#)]
120. Nasiri, H.R.; Hohmann, K.; Hatemler, M.G.; Plodek, A.; Bracher, F.; Schwalbe, H. In vitro production of reactive oxygen species (ROS) by sampangine. *Med. Chem. Res.* **2017**, *26*, 1170–1175. [[CrossRef](#)]
121. Oanh, N.T.T.; Tung, T.H.; Hue, C.T.; Thanh, L.N.; Thao, D.T.; Hang, N.T.M. Two new alkaloids from *Polyalthia nemoralis*. *Nat. Prod. Commun.* **2017**, *12*, 1025–1027. [[CrossRef](#)]
122. Orabi, K.Y.; Clark, A.M.; Hufford, C.D. Microbial transformation of benzosampangine. *J. Nat. Prod.* **2000**, *63*, 396–398. [[CrossRef](#)]
123. Agarwal, A.K.; Xu, T.; Jacob, M.R.; Feng, Q.; Lorenz, M.C.; Walker, L.A.; Clark, A.M. Role of heme in the antifungal activity of the azaoxoaporphine alkaloid sampangine. *Eukaryot. Cell* **2007**, *7*, 387–400. [[CrossRef](#)] [[PubMed](#)]
124. Peterson, J.R.; Zjawiony, J.; Liu, S.; Hufford, C.D.; Clark, A.M.; Rogers, R.D. Copyrine alkaloids: Synthesis, spectroscopic characterization, and antimycotic/antimycobacterial activity of A- and B-ring-functionalized sampangines. *J. Med. Chem.* **1992**, *35*, 4069–4077. [[CrossRef](#)] [[PubMed](#)]
125. Leboeuf, M.; Cavé, A. Alkaloids of annonaceae. XIV. Identification of canangine and eupolauridine, new alkaloids with a naphthyridine nucleus. *Lloydia* **1976**, *39*, 459–460. [[PubMed](#)]
126. Bowden, B.; Ritchie, E.; Taylor, W. Constituents of eupomatia species. II. isolation and structure determination of further eupomatoid lignans from the bark of *Eupomatia laurina*. *Aust. J. Chem.* **1972**, *25*, 2659–2669. [[CrossRef](#)]
127. Hufford, C.D.; Liu, S.; Clark, A.M.; Oguntimein, B.O. Anticandidal activity of eupolauridine and onychine, alkaloids from *Cleistopholis patens*. *J. Nat. Prod.* **1987**, *50*, 961–964. [[CrossRef](#)] [[PubMed](#)]

128. Liew, S.Y.; Mukhtar, M.R.; Hadi, A.H.A.; Awang, K.; Mustafa, M.R.; Zaima, K.; Morita, H.; Litaudon, M. Naucline, a new indole alkaloid from the bark of *Nauclea officinalis*. *Molecules* **2012**, *17*, 4028–4036. [[CrossRef](#)]
129. Mukhtar, M.R.; Osman, N.; Awang, K.; Hazni, H.; Qureshi, A.K.; Hadi, A.H.A.; Zaima, K.; Morita, H.; Litaudon, M. Neonaucine, a new indole alkaloid from the leaves of *Ochreinauclea maingayii* (Hook. f.) Ridsd. *Molecules* **2011**, *17*, 267–274. [[CrossRef](#)]
130. Ai, Y.; He, H.; Chen, P.; Yan, B.; Zhang, W.; Ding, Z.; Li, D.; Chen, J.; Ma, Y.; Cao, Y.; et al. An alkaloid initiates phosphodiesterase 3A-schlafen 12 dependent apoptosis without affecting the phosphodiesterase activity. *Nat. Commun.* **2020**, *11*, 1–10. [[CrossRef](#)] [[PubMed](#)]
131. Massiot, G.; Thépenier, P.; Jacquier, M.-J.; Le Men-Olivier, L.; Verpoorte, R.; Delaude, C. Alkaloids of *Strychnos johnsonii*. *Phytochemistry* **1987**, *26*, 2839–2846. [[CrossRef](#)]
132. Taher, M.; Shaari, S.S.; Susanti, D.; Arbain, D.; Zakaria, Z.A. Genus ophiorrhiza: A review of its distribution, traditional uses, phytochemistry, biological activities and propagation. *Molecules* **2020**, *25*, 2611. [[CrossRef](#)] [[PubMed](#)]
133. Abreu, P.; Pereira, A. A new indole alkaloid from *Sarcocephalus latifolius*. *Heterocycles* **1998**, *48*, 885. [[CrossRef](#)]
134. Caprasse, M.; Houssier, C. Do planar alkaloids from *Strychnos usambarensis* intercalate into the DNA helix? *Biochimie* **1983**, *65*, 157–167. [[CrossRef](#)]
135. Lederer, E.; Teissier, G.; Hutterer, C. The isolation and chemical composition of calliactine, pigment of the sea anemone “*Sagartia parasitica*” (*Calliactis effoeta*). *Bull. Soc. Chim. Fr.* **1940**, *7*, 608–615.
136. Molinski, T.F. Marine pyridoacridine alkaloids: Structure, synthesis, and biological chemistry. *Chem. Rev.* **1993**, *93*, 1825–1838. [[CrossRef](#)]
137. Delfourne, E.; Kiss, R.; Le Corre, L.; Dujols, F.; Bastide, J.; Collignon, F.; Lesur, B.; Frydman, A.; Darro, F. Synthesis and in vitro antitumor activity of ring C and D-substituted phenanthroline-7-one derivatives, analogues of the marine pyridoacridine alkaloids ascididemin and meridine. *Bioorg. Med. Chem.* **2004**, *12*, 3987–3994. [[CrossRef](#)]
138. Bontemps, N.; Bry, D.; Lopez-Legentil, S.; Simon-Levert, A.; Long, C.; Banaigs, B. Structures and antimicrobial activities of pyridoacridine alkaloids isolated from different chromotypes of the ascidian *Cystodytes dellechiaiei*. *J. Nat. Prod.* **2010**, *73*, 1044–1048. [[CrossRef](#)]
139. Skyler, D.; Heathcock, C.H. The pyridoacridine family tree: A useful scheme for designing synthesis and predicting undiscovered natural products. *J. Nat. Prod.* **2002**, *65*, 1573–1581. [[CrossRef](#)]
140. Kobayashi, J.; Cheng, J.; Wálchli, M.R.; Nakamura, H.; Hirata, Y.; Takuma Sasaki, L.; Ohizumi, Y. Cystodytins A, B, and C, novel tetracyclic alkaloids with potent antineoplastic from the Okinawan tunicate *Cystodytes dellechiaiei*. *J. Org. Chem.* **1988**, *53*, 1800–1804. [[CrossRef](#)]
141. Kobayashi, J.; Tsuda, M.; Tanabe, A.; Ishibashi, M.; Cheng, J.-F.; Yamamura, S.; Sasaki, T. Cystodytins D-I, new cytotoxic tetracyclic aromatic alkaloids from the Okinawan marine tunicate *Cystodytes dellechiaiei*. *J. Nat. Prod.* **1991**, *54*, 1634–1638. [[CrossRef](#)] [[PubMed](#)]
142. McDonald, L.A.; Eldredge, G.S.; Barrows, L.R.; Ireland, C.M. Inhibition of topoisomerase II catalytic activity by pyridoacridine alkaloids from a *Cystodytes* sp. ascidian: A mechanism for the apparent intercalator-induced inhibition of topoisomerase II. *J. Med. Chem.* **1994**, *37*, 3819–3827. [[CrossRef](#)]
143. Appleton, D.R.; Pearce, A.; Lambert, G.; Babcock, R.C.; Copp, B.R. Isodiplamine, cystodytin K and lissoclinidine: Novel bioactive alkaloids from the New Zealand ascidian *Lissoclinum notti*. *Tetrahedron* **2002**, *58*, 9779–9783. [[CrossRef](#)]
144. Copp, B.R.; Jompa, J.; Tahir, A.; Ireland, C.M. Styelsamines A–D: New tetracyclic pyridoacridine alkaloids from the Indonesian ascidian *Eusynstyela Latericius*. *J. Org. Chem.* **1998**, *63*, 8024–8026. [[CrossRef](#)]
145. Bry, D.; Banaigs, B.; Long, C.; Bontemps, N. New pyridoacridine alkaloids from the purple morph of the ascidian *Cystodytes dellechiaiei*. *Tetrahedron Lett.* **2011**, *52*, 3041–3044. [[CrossRef](#)]
146. Fong, H.K.H.; Copp, B.R. Synthesis, DNA Binding and Antitumor Evaluation of Styelsamine and Cystodytin Analogues. *Mar. Drugs* **2013**, *11*, 274–299. [[CrossRef](#)]
147. Charyulu, G.A.; McKee, T.C.; Ireland, C.M. Diplamine, a cytotoxic polyaromatic alkaloid from the tunicate *Diplosoma* sp. *Tetrahedron Lett.* **1989**, *30*, 4201–4202. [[CrossRef](#)]
148. Clement, J.A.; Kitagaki, J.; Yang, Y.; Saucedo, C.J.; O’Keefe, B.R.; Weissman, A.M.; McKee, T.C.; McMahon, J.B. Discovery of new pyridoacridine alkaloids from *Lissoclinum c* F. Badium that inhibit the ubiquitin ligase activity of Hdm2 and stabilize p53. *Bioorg. Med. Chem.* **2008**, *16*, 10022–10028. [[CrossRef](#)]
149. Searle, P.A.; Molinski, T.F. Five new alkaloids from the tropical ascidian, *Lissoclinum* sp. lissoclinotoxin A is chiral. *J. Org. Chem.* **1994**, *59*, 6600–6605. [[CrossRef](#)]
150. Molinski, T.F.; Ireland, C.M. Varamines A and B, new cytotoxic thioalkaloids from *Lissoclinum vareau*. *J. Org. Chem.* **1989**, *54*, 4256–4259. [[CrossRef](#)]
151. Rudi, A.; Benayahu, Y.; Goldberg, I.; Kashmana, Y. Alkaloid metabolites of the marine tunicate: Segoline A, isosegoline A and nor-segoline. *Tetrahedron Lett.* **1988**, *29*, 3861–3862. [[CrossRef](#)]
152. Rudi, A.; Kashman, Y. Six new alkaloids from the purple Red Sea tunicate *Eudistoma* sp. *J. Org. Chem.* **1989**, *54*, 5331–5337. [[CrossRef](#)]
153. Einat, M.; Nagler, A.; Lishner, M.; Amiel, A.; Yarkoni, S.; Rudi, A.; Gellerman, G.; Kashman, Y.; Fabian, I. Potent antileukemic activity of the novel agents norsegoline and dibezine. *Clin. Cancer Res.* **1995**, *1*, 823–829. [[PubMed](#)]

154. Kim, J.; Pordesimo, E.O.; Toth, S.I.; Schmitz, F.J.; Van Altena, I. Pantherinine, a cytotoxic aromatic alkaloid, and 7-deazainosine from the ascidian *Aplidium pantherinum*. *J. Nat. Prod.* **1993**, *56*, 1813–1816. [[CrossRef](#)] [[PubMed](#)]
155. Kim, S.K. *Handbook of Anticancer Drugs from Marine Origin*; Springer: Berlin, Germany, 2015.
156. Carrol, A.R.; Scheuer, P.J. Kuanoniamines A, B, C, and D: Pentacyclic alkaloids from a tunicate and its prosobranch mollusk predator *Chelynotus semperi*. *J. Org. Chem.* **1990**, *55*, 4426–4431. [[CrossRef](#)]
157. Eder, C.; Schupp, P.; Proksch, P.; Wray, V.; Steube, K.; Muller, C.E.; Frobenius, W.; Herderich, M.; Van Soest, R.W.M. Bioactive pyridoacridine alkaloids from the *Micronesian sponge Oceanapia* sp. *J. Nat. Prod.* **1998**, *61*, 301–305. [[CrossRef](#)]
158. Bontemps, N.; Gattaceca, F.; Long, C.; Thomas, O.P.; Banaigs, B. Additional cytotoxic pyridoacridine alkaloids from the ascidian *Cystodytes violatinctus* and biogenetic considerations. *J. Nat. Prod.* **2013**, *76*, 1801–1805. [[CrossRef](#)]
159. Salomon, C.E.; Faulkner, D.J. Sagitol, a pyridoacridine alkaloid from the sponge *Oceanapia sagittaria*. *Tetrahedron Lett.* **1996**, *37*, 9147–9148. [[CrossRef](#)]
160. Utkina, N.K. Sagitol D, a new thiazole containing pyridoacridine alkaloid from a vietnamese ascidian. *Nat. Prod. Commun.* **2015**, *10*, 1547–1548. [[CrossRef](#)] [[PubMed](#)]
161. Ibrahim, S.R.; Mohamed, G.A.; Elkhayat, E.S.; Fouad, M.A.; Proksch, P. Sagitol C, a new cytotoxic pyridoacridine alkaloid from the sponge *Oceanapia* sp. *Bull. Fac. Pharm. Cairo Univ.* **2013**, *51*, 229–232. [[CrossRef](#)]
162. Gunawardana, G.P.; Koehn, F.E.; Lee, A.Y.; Clardy, J.; He, H.Y.; Faulkner, D.J. Pyridoacridine alkaloids from deep-water marine sponges of the family Pachastrellidae: Structure revision of dercitin and related compounds and correlation with the kuanoniamines. *J. Org. Chem.* **1992**, *57*, 1523–1526. [[CrossRef](#)]
163. Gunawardana, G.P.; Kohmoto, S.; Gunasekera, S.P.; McConnell, O.J.; Koehn, F.E. Dercitine, a new biologically active acridine alkaloid from a deep water marine sponge, *Dercitus* sp. *J. Am. Chem. Soc.* **1988**, *110*, 4856–4858. [[CrossRef](#)]
164. Gunawardana, G.P.; Kohmoto, S.; Burres, N.S. New cytotoxic acridine alkaloids from two deep water marine sponges of the family. *Tetrahedron Lett.* **1989**, *30*, 4359–4362. [[CrossRef](#)]
165. Burres, N.S.; Sazesh, S.; Gunawardana, G.P.; Clement, J.J. Antitumor activity and nucleic acid binding properties of dercitin, a new acridine alkaloid isolated from a marine *Dercitus* species sponge. *Cancer Res.* **1989**, *49*, 5267–5274.
166. Gullo, V.P. *Discovery of Novel Natural Products with Therapeutic Potential*; Newnes: Oxford, UK, 2013.
167. Torres, Y.R.; Bugni, T.S.; Berlinck, R.G.S.; Ireland, C.M.; Ferreira, A.G.; da Rocha, R.M. Sebastianines A and B, novel biologically active pyridoacridine alkaloids from the Brazilian ascidian *Cystodytes dellechiaiei*. *J. Org. Chem.* **2002**, *67*, 5429–5432. [[CrossRef](#)]
168. Plubrukarn, A.; Davidson, B.S. Arnoamines A and B, new cytotoxic pentacyclic pyridoacridine alkaloids from the ascidian *Cystodytes* sp. *J. Org. Chem.* **1998**, *63*, 1657–1659. [[CrossRef](#)]
169. Schmitz, F.J.; Agarwal, S.K.; Gunasekera, S.P.; Schmidt, P.G.; Shoolery, J.N. Amphimedine, new aromatic alkaloid from a pacific sponge, *Amphimedon* sp. Carbon connectivity determination from natural abundance carbon-13-carbon-13 coupling constants. *J. Am. Chem. Soc.* **1983**, *105*, 4835–4836. [[CrossRef](#)]
170. Wei, X.; Bugni, T.S.; Harper, M.K.; Sandoval, I.T.; Manos, E.J.; Swift, J.; Van Wagoner, R.M.; Jones, D.A.; Ireland, C.M. evaluation of pyridoacridine alkaloids in a zebrafish phenotypic assay. *Mar. Drugs* **2010**, *8*, 1769–1778. [[CrossRef](#)] [[PubMed](#)]
171. De Guzman, F.S.; Carte, B.; Troupe, N.; Faulkner, D.J.; Harper, M.K.; Concepcion, G.P.; Mangalindan, G.C.; Matsumoto, S.S.; Barrows, L.R.; Ireland, C.M. Neoamphimedine: A new pyridoacridine topoisomerase II inhibitor which catenates DNA. *J. Org. Chem.* **1999**, *64*, 1400–1402. [[CrossRef](#)]
172. Tasdemir, D.; Marshall, K.M.; Mangalindan, G.C.; Concepcion, G.P.; Barrows, L.R.; Harper, M.K.; Ireland, C.M. Deoxyamphimedine, a New pyridoacridine alkaloid from two tropical *Xestospongia* sponges. *J. Org. Chem.* **2001**, *66*, 3246–3248. [[CrossRef](#)]
173. Marshall, K.; Barrows, L.R. Biological activities of pyridoacridines. *Nat. Prod. Rep.* **2004**, *21*, 731–751. [[CrossRef](#)] [[PubMed](#)]
174. Nukoolkarn, V.S.; Saen-Oon, S.; Rungrotmongkol, T.; Hannongbua, S.; Ingkaninan, K.; Suwanborirux, K. Petrosamine, a potent anticholinesterase pyridoacridine alkaloid from a Thai marine sponge *Petrosia n.* sp. *Bioorg. Med. Chem.* **2008**, *16*, 6560–6567. [[CrossRef](#)] [[PubMed](#)]
175. Carroll, A.R.; Ngo, A.; Quinn, R.J.; Redburn, J.; Hooper, J.N.A. Petrosamine B, an Inhibitor of the helicobacte rpylori enzyme aspartyl semialdehyde dehydrogenase from the Australian sponge *Oceanapia* sp. *J. Nat. Prod.* **2005**, *68*, 804–806. [[CrossRef](#)] [[PubMed](#)]
176. Feng, Y.; Davis, R.; Sykes, M.L.; Avery, V.; Carroll, A.; Camp, D.; Quinn, R.J. Antitrypanosomal pyridoacridine alkaloids from the Australian ascidian *Polysyncraton echinatum*. *Tetrahedron Lett.* **2010**, *51*, 2477–2479. [[CrossRef](#)]
177. Lindsay, B.S.; Barrows, L.R.; Copp, B. Structural requirements for biological activity of the marine alkaloid ascididemin. *Bioorg. Med. Chem. Lett.* **1995**, *5*, 739–742. [[CrossRef](#)]
178. Appleton, D.R.; Pearce, A.N.; Copp, B.R. Anti-tuberculosis natural products: Synthesis and biological evaluation of pyridoacridine alkaloids related to ascididemin. *Tetrahedron* **2010**, *66*, 4977–4986. [[CrossRef](#)]
179. Delfourne, E.; Bastide, J. Marine pyridoacridine alkaloids and synthetic analogues as antitumor agents. *Med. Res. Rev.* **2002**, *23*, 234–252. [[CrossRef](#)] [[PubMed](#)]
180. Schmitz, F.J.; DeGuzman, F.S.; Hossain, M.B.; Van der Helm, D. Cytotoxic aromatic alkaloids from the ascidian *Amphicarpa meridiana* and *Leptoclinides* sp.: Meridine and 11-hydroxyascididemin. *J. Org. Chem.* **1991**, *56*, 804–808. [[CrossRef](#)]
181. Barnes, E.C.; Said, N.A.B.; Williams, E.; Hooper, J.; Davis, R.A. Ecionines A and B, two new cytotoxic pyridoacridine alkaloids from the Australian marine sponge, *Ecionemia geodides*. *Tetrahedron* **2010**, *66*, 283–287. [[CrossRef](#)]

182. Tran, T.; Pham, N.B.; Quinn, R.J. Structure determination of pentacyclic pyridoacridine alkaloids from the Australian marine organisms *Ancorina geodides* and *Cnemidocarpa stolonifera*. *Eur. J. Org. Chem.* **2014**, *2014*, 4805–4816. [[CrossRef](#)]
183. Carroll, A.R.; Cooray, N.M.; Poiner, A.; Scheuer, P.J. A second shermilamine alkaloid from a tunicate *Trididemnum* sp. *J. Org. Chem.* **1989**, *54*, 4231–4232. [[CrossRef](#)]
184. Cooray, N.M.; Scheuer, P.J.; Parkanyi, L.; Clardy, J. Shermilamine A: A pentacyclic alkaloid from a tunicate. *J. Org. Chem.* **1988**, *53*, 4619–4620. [[CrossRef](#)]
185. Koren-Goldshlager, G.; Akin, M.; Gaydou, E.M.; Kashman, Y. Three new alkaloids from the marine tunicate *Cystodytes violatinctus*. *J. Org. Chem.* **1998**, *63*, 4601–4603. [[CrossRef](#)]
186. Luedtke, N.W.; Hwang, J.S.; Glazer, E.; Gut, D.; Kol, M.; Tor, Y. Eilatin Ru(II) complexes display anti-HIV activity and enantiomeric diversity in the binding of RNA. *ChemBioChem* **2002**, *3*, 766–771. [[CrossRef](#)]
187. Zeng, C.-M.; Ishibashi, M.; Matsumoto, K.; Nakaïke, S.; Kobayashi, J. Two new polycyclic aromatic alkaloids from the Okinawan marine sponge *Biemna* sp. *Tetrahedron* **1993**, *49*, 8337–8342. [[CrossRef](#)]
188. Aoki, S.; Wei, H.; Matsui, K.; Rachmat, R.; Kobayashi, M. Pyridoacridine alkaloids inducing neuronal differentiation in a neuroblastoma cell line, from marine sponge *Biemna fortis*. *Bioorg. Med. Chem.* **2003**, *11*, 1969–1973. [[CrossRef](#)]